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Abstract
Imprinting is a mammalian adaptation that results in the mono-allelic expression of a
subset of genes depending on their parental origin. It is believed that DNA methylation
marks are responsible for maintaining imprinted gene expression patterns. The 'parental
conflict' hypothesis was proposed to explain the evolution of imprinting and is based on
the assumption that mammals arose from an ancestor that was polyandrous (multiple
fathers within one litter). According to this hypothesis, conflict between the male and
female over the allocation of maternal resources to the offspring led to the evolution of
imprinting. Consistent with this, many imprinted genes are involved in embryonic or
placental growth by regulating mitogenic pathways or the cell cycle. Loss of imprinting
(LOI) has been found at specific loci in cancers, raising the possibility that altered
expression of imprinted genes may also contribute to tumorigenesis. To investigate the
effect of global LOI on embryonic development and cancer formation, imprint free (IF)
embryonic stem (ES) cells were generated using conditional inactivation/reactivation of
the DNA methyltransferase Dnmtl. Tetraploid complementation and chimera
experiments revealed that IF-embryos fail to develop beyond E1 1.5 and display an
overgrowth phenotype. As developmental comparisons, parthenogenetic and
androgenetic (AT) embryos were derived and found to develop to E9.5 and E7.5,
respectively. Removing the imprinted methyl marks from AT-ES cells rescued
embryonic development to E9.5-10.5 and restored pluripotency. However, IFAT
embryos were not developmentally equivalent to biparentally-derived IF-embryos,
suggesting that mechanisms other than DNA methylation may be involved in maintaining
parent-specific gene expression patterns. To study the effect of LOI on cell growth,
murine embryonic fibroblasts (MEFs) were derived from E13.5 chimeric IF-embryos and
analyzed in vitro. IF-MEFs grew faster, were resistant to the cytostatic effects of TGFI3,
and formed tumors in SCID mice. In addition, IF-MEFs were immortal and when
exposed to H-Ras became fully transformed. Western blot analysis of IF-MEFs revealed
abnormally low levels of p19 Arf and p53, two critical regulators of growth arrest and
potent tumor suppressors. Somatic contribution of IF-ES cells in chimeric adults led to
highly penetrant tumor formation by 12 months of age, causing multiple cancer types
derived from the IF cells. Taken together, these data are consistent with global LOI
having a causal role in tumorigenesis by affecting the regulation of the p53-p19Ar
pathway and predisposing IF cells to transformation.
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Chapter 1:
Introduction
1.1 Epigenetic regulation of gene expression during development and disease.
Epigenetics is used to describe the study of stable alterations in gene expression
potential that arise during development and cellular proliferation (reviewed by Jaenisch
and Bird, 2002). These epigenetic processes are essential for embryogenesis, cellular
differentiation and tissue maintenance in mammals. In addition, epigenetic modifications
provide safeguards to prevent viral genomes commandeering cellular processes for their
own replication. Two epigenetic mechanisms that fulfill this criterion are DNA
methylation and genomic imprinting.
1.1.1 DNA methylation
Methylation is a common form of DNA modification in animals, occurring at position
five of cytosine residues (reviewed in Bird and Wolffe 1999) and (Bestor 2000)). The
mammalian genome contains approximately 3 x 107 of 5-methylcytosine (m5C) residues
most of this is within 5'- m5CpG-3' dinucleotides, which is roughly equivalent to 1% of
the genome (Walsh and Bestor 1999). Like histone modifications cytosine methylation
raises the coding capacity of the genome and participates in the partitioning of genomes
into active and inactive functional compartments. Some of the constituents of the
inactive compartment associated with DNA methylation include imprinted genes, the
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inactive female X chromosome, and parasitic DNA elements. It was proposed in 1975
that DNA methylation might be responsible for the stable maintenance of a particular
gene expression pattern through mitotic cell division (Holliday and Pugh 1975; Riggs
1975). Since then, ample evidence has been obtained to support this concept, and DNA
methylation is now recognized to be a significant contributor to the stability of gene
expression states (Bird 2002). Specifically, DNA methylation establishes a silent
chromatin state by collaborating with proteins that modify nucleosomes.
1.1.1.1 The DNA methyltransferases of mammals
Cellular DNA methylation patterns seem to be established by a complex interplay of
at least three independent DNA methyltansferases: Dnmtl, Dnmt3A, Dnmt3B and
Dnmt3L (Fig 1.1). Genetic analysis of these various Dnmts has established that DNA
methylation is essential for vertebrate development (Bestor 2000). Loss of methylation
causes apoptosis in embryos and in fibroblasts but not in ES cells or in cancer cells
(Jaenisch and Bird 2003).
1.1.1.1.1 Catalytic mechanism of DNA (cytosine-5)-methyltransferases
The 5 carbon position of cytosine is relatively unreactive, and its methylation in
neutral aqueous solution has been called a 'chemically improbable reaction (Chen,
MacMillan et al. 1991). Co-crystal structures of DNA-DNA methyltransferases showed
that the target cytosine is everted from the DNA helix and inserted deep into the active
site of the enzyme (Klimasauskas, Kumar et al. 1994).
10
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Figure 1.1 DNA Methyltransferases in mammals
Cys-rich Catalytic domain-.------~===========-vs.=..:..==. I:.=- Dnmt1
I IV VIII IX X
Cys-rich
Dnmt3A
Cys-rich
Dnmt3B
Cys-rich____ Dnmt3L
Sequence relationships among mammalian DNA methyltransferases. Catalytic
motifs are designated with roman numerals. Motifs are absent from Dnmt3L,
whereas the cysteine-rich regions and other sequences show strong similari-
ties with Dnmt3A and Dnmt3B. At right is a ClustalW representation of
sequence similarities within the region spanning catalytic motifs I to VIII. The
corresponding region of Dnmt3L was identified by alignment with Dnmt3A and
Dnmt3B. Adapted from Bourc'his et al 2001 .
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DNA methyl transferases add a methyl group to the 6 position, thereby pushing
electrons to the 5 position, which then attack the methyl group of S-adenosyl-L-
methionine resulting in 5-methylcytosine (Fig 1.2) (Bestor 2000).
1.1.1.1.2 DNA methyltransferase-1 (Dnmtl)
Dnmtl was the first methyltransferase to be discovered (Bestor, Laudano et al.
1988). Pioneering work has established that Dnmtl has a 10-40 fold preference for
methylating hemimethylated DNA (Yoder, Soman et al. 1997). Dnmtl is the most
abundant methyltransferase in somatic cells and localizes to replication foci in S phase
where it interacts with the proliferating cell nuclear antigen (PCNA) (ida, Suetake et al.
2002). Dnmtl is often referred to as the maintenance methyltransferase because it is
believed to be the enzyme responsible for copying methylation patterns after DNA
replication. Homologues of Dnmtl have been found in nearly all eukaryotes whose DNA
bears m5CpG but not in those that lack it, indicating that methyltransferases have an
important and conserved function in DNA methylation (Bestor 2000).
Targeted mutations of the Dnmtl gene result in a recessive lethal phenotype and
produce a number of unique phenotypes in mice (Li, Bestor et al. 1992). Firstly, the
Dnmtl mutation produces a lethal differentiation phenotype in which homozygous
mutant embryonic stem (ES) cells grow normally with a severely demethylated genome
but undergo cell-autonomous apoptosis when induced to differentiate (Li, Bestor et al.
1992). Secondly, embryos homozygous for mutations at Dnmtl show mis-expression of
imprinted genes (Li, Beard et al. 1993; Li, Beard et al. 1993).
12
Figure 1.2 Cytosine Methylation in Vertebrates.
Cytosine
H
H
~
Methyltransferase N I
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Figure 1.2 Cytosine Methylation in Vertebrates
Addition of a methyl group to cytosine by methyltransferases results in 5-mehtyl-
cytosine
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Finally, homozygous Dnmtl-null embryos display transient ectopic expression of
all copies of Xist and faults in X-inactivation (Beard, Li et al. 1995). ES cells in a
demethylated state for extended lengths of time have an increased frequency of
chromosomal deletions and rearrangements, most likely due to an increased rate of
homologous recombination among demethylated and unmasked repeat sequences (Chen,
Pettersson et al. 1998). The finding that a small amount of m5C persist in the genome of
Dnmtl-null ES cells and that these cells partially retain the capacity to methylate newly
integrated retroviral DNA, is consistent with the existence of one or more additional
DNA methyltransferases (Lei, Oh et al. 1996).
Interestingly, Dnmtl is localized exclusively to the nuclei of somatic cells and is
cytoplasmic only in the oocyte and preimplantation embryo. Expression of Dnmtl is
controlled by multiple promoters (including female- and male-specific) and results in
transcripts with alternative 5' exons (Fig 1.3). Usage of the oocyte specific promoter
leads to translation of a protein that is shorter than the full-length (somatic) form by 118
N-terminal amino acids (Mertineit, Yoder et al. 1998). This truncated oocyte specific
form of Dnmtl (Dnmtlo) is enzymatically active and accumulates to very high levels in
the oocyte; it is nuclear only at the earliest stages of oocyte growth and becomes
localized to the cytoplasmic shell of the oocyte prior to ovulation (Carlson, Page et al.
1992). After fertilization the Dnmtl o protein is cytoplasmic in pre-implantation embryos
but enters, and then exits, the nucleus at the 8-cell stage (Mertineit, Yoder et al. 1998)
(Carlson, Page et al. 1992).
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Figure 1.3 Sex-specific exons and mRNAs from the Dnmt1 gene
a
b
~
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2kb
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Oocyte.specffic: High levels of truncated protein with full activity_.1 -An
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Somatic cell-specific: Ful-Iength Dnmt1II ---
1s
Figure 1.3 Sex-specific exons and mRNAs from the Dnmt1 gene.
(a) 51 region of Dnmt1 on proximal mouse chromosome 9. Exon 10 is oocyte-specific,
exon 1s is specific to somatic cells of both sexes and exon 1p is restricted to pachy-
tene spermatocytes (30). The ATG codon in exon 1s is used for initiation of translation
in somatic cells; a truncated form arises from use of the ATG codon in exon 4 in
oocytes (30). (b) mRNA products of sex-specific exons. Effect of the alternative
promoter use and splicing on organization of mature Dnmt1 mRNAs are indicated.
Heavy horizontal bars indicate open reading frames; short vertical bars indicate ATG
initiation codons. Adapted from Bestor et al 2000.
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Dnmtl does not become fully nuclear again until after implantation, following its
replacement by the full-length somatic form, which is transcribed from the somatic cell
promoter. The biological function of the elaborate nuclear-cytoplasmic trafficking of
Dnmtl during oogenesis and early development is currently unknown, although targeted
mutation of Dnmtlo results in a loss of maternal imprints (Howell, Bestor et al. 2001).
Promoter s, located 7 kb upstream of exon lo, is active in somatic cells and
functions as the housekeeping promoter (Yoder, Soman et al. 1997). Exon s contains
the ATG codon that initiates full-length Dnmtl (Mertineit, Yoder et al. 1998). Promoter
is is activated shortly after implantation and by embryonic day (E)7, all detectable
Dnmtl protein is the s full-length form (Mertineit, Yoder et al. 1998). Although is
promoter is active in all dividing cells, it does become downregulated under conditions of
growth arrest (Mertineit, Yoder et al. 1998).
Promoter p, lying downstream of exon s, is active only in the pachytene
spermatocyte (Mertineit, Yoder et al. 1998). Exon lp contains multiple short open
reading frames that are predicted to interfere with translation of the Dnmtl open reading
frame. In keeping with this expectation, the pachytene spermatocyte does not contain
detectable amounts of the Dnmtl protein and the abundant mRNA that contains exon lp
is not associated with polyribosomes (Trasler, Alcivar et al. 1992; Mertineit, Yoder et al.
1998).
The relationship between Dnmtl protein and mRNA levels in germ cells is
unusual. The protein is present at very high levels in mature oocytes and preimplantation
embryos, but mRNA levels are low at these stages. Conversely, Dnmtl mRNA levels in
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the pachytene spermatocyte are high, but protein levels are low. An analysis of mRNA
levels therefore gives a large underestimate of protein levels in oocytes and early
embryos, and a significant overestimate in pachytene spermatocytes (Mertineit, Yoder et
al. 1998).
1.1.1.1.3 Dnmt3a, 3b and 3L
More recently, the Dnmt3 family of methyltransferase genes from mouse and
human have been characterized (Okano, Bell et al. 1999). These genes are highly
conserved and orthologues have been identified in zebrafish, Arabidopsis thaliana and
maize (Bestor 2000).
In mice, Dnmt3a and Dnmt3b are highly expressed in the developing implantation
embryo (Okano, Bell et al. 1999). Functional studies in transgenic flies have shown that
Dnmt3a can carryout de novo DNA methylation (Lyko, Ramsahoye et al. 1999).
Surprisingly, Dnmt3a knockout mice are born live but become runted and die around four
weeks of age (Okano, Bell et al. 1999). These observations, coupled with in vitro data
indicating that Dnmt3A and Dnmt3B enzymes have an equal preference for hemi- and
unmethylated DNA substrates have led to them being termed the 'de novo DNA
methyltransferases' (Okano, Xie et al. 1998)
In humans, mutations in DNMT3B are responsible for intercranial facial (ICF)
syndrome (Wijmenga, van den Heuvel et al. 1998) and DNMT3B currently remains the
only DNA methyltransferase to be mutated in a human disease. The ICF syndrome
results in immunodeficiency and mild facial anomalies, in addition numerous cytogenetic
abnormalities that largely affect the pericentric regions of chromosome 1, 9 and 16 have
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been observed. These pericentric regions contain a type of repetitive DNA termed
'classical satellite', or 'satellites 2 and 3', and are normally heavily methylated. In ICF
patients, the classical satellite regions are nearly completely unmethylated, as are CpG
islands on the inactive X chromosome (Jeanpierre, Turleau et al. 1993; Kondo, Bobek et
al. 2000). Thus, DNMT3B appears to be specialized for the methylation of only a
particular compartment of the genome. To date, none of the ICF patients have been
found to be homozygous for null alleles of DNMT3B (Xu, Bestor et al. 1999). This
suggests that complete loss of DNMT3B activity might be lethal and in support of this,
Dnmt3b knockout mice are non-viable and show numerous developmental defects and
growth impairment after E9.5 (Okano, Bell et al. 1999).
Dnmt3L by itself has no catalytic DNA methyltransferase activity. However, it
does co-localize with Dnmt3a and Dnmt3b within the cell, and is essential for
establishing methylation imprints in both the female and male germline (Bourc'his, Xu et
al. 2001; Hata, Okano et al. 2002).
1.1.1.2 Mammalian DNA methylation patterns
The pattern of DNA methylation during mammalian embryogenesis is dynamic,
beginning with a wave of demethylation during the cleavage stages, followed by genome-
wide de novo methylation after implantation (Jaenisch 1997). Demethylation is an active
process that strips the male genome of methylation within hours of fertilization (Mayer,
Niveleau et al. 2000; Oswald, Engemann et al. 2000). In contrast the maternal genome is
passively demethylated during subsequent cleavage divisions (Li 2002). The extent of
methylation in the genome of the gastrulating embryo is high due to de novo methylation
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but it tends to decrease in specific tissues during differentiation (Ehrlich, Gama-Sosa et
al. 1982). De novo methylation occurs rarely during normal postgastrulation
development but it is observed frequently during the establishment of cell lines and in
some cancers (Jones, Wolkowicz et al. 1990; Kawai, Hirose et al. 1994). (Fig 1.4)
One of the most striking features of vertebrate DNA methylation patterns is the
presence of CpG islands. These GC-rich regions of DNA possess high densities of CpGs
that are usually positioned at the 5' ends of genes. Initial computational studies have
estimated that the human genome contains a predicted 29,000 CpG islands, most of
which remain unmethylated throughout embryonic development and in adults (Robertson
and Wolffe 2000; Egger, Liang et al. 2004). However, a small proportion of CpG islands
become methylated during development and as a consequence the associated promoter is
stably silenced. This process of developmentally programmed methylation is also
involved in genomic imprinting (see section 1.1.2 below) and X chromosome inactivation
(Jaenisch and Bird 2003). While the de novo methylation events that occur in germ cells
or during early embryogenesis occur rapidly, the rate of accumulation of methylated
CpGs in somatic cells appears to be very slow. For example, the de novo methylation of
a provirus in murine erythroleukemia cells takes many weeks to complete (Bird and
Wolffe 1999). Similarly, the recovery of global DNA methylation levels following
chronic treatment of mouse cells with the DNA methylation inhibitor 5-azacytidine
requires months to complete (Egger, Liang et al. 2004).
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Figure 1.4 Temporal changes in DNA methylation levels during development
Primordial
germ cells
I Adult I,,
Maintenance
Methylation
~ .Do novoMethylation~ .
Somatic
lineages
Demethylation
~ .
Developmental Time
Figure 1.4 Temporal changes in DNA methylation levels during development.
Shows the changes in the global levels of genomic methylation relative to the different
stages of embryonic development and the somatic and germ cell lineages. Adapted
from Jaenisch 1997.
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1.1.1.3 The function of DNA methylation
1.1.1.3.1 Genome defense and structural integrity
Much attention in the methylation field has focused on CpG islands, primarily
because of the propensity of these sequences to become aberrantly hypermethylated in
tumors, resulting in the transcriptional silencing of their associated gene (Baylin, Herman
et al. 1998; Jones and Laird 1999). Most CpG-dinucleotides however, reside in the
relatively CpG-poor bulk genomic DNA and are hypermethylated (Cooper and Krawczak
1989). A closer examination of the distribution of this fraction of CpG dinucleotides
within the genome has revealed that most reside within parasitic DNA elements or
retrotransposons, such as endogenous retroviruses, LINE elements and SINE elements,
which are CpG-rich (Yoder, Walsh et al. 1997; Colot and Rossignol 1999). These
parasitic elements account for almost 40% of the human genome and it is thought that
DNA methylation may have arisen as a genome defense system to silence expression of
these elements and limit their spread throughout the genome (Yoder, Walsh et al. 1997).
Parasitic DNA elements represent a significant threat to the structural integrity of the
genome because they can mediate recombination between non-allelic repeats, resulting in
chromosomal rearrangements and translocations. In addition, active retrotransposons can
integrate into, and disrupt the expression or function of, host genes (Kazazian and Moran
1998; Montagna, Santacatterina et al. 1999). For instance, many retrotransposons contain
strong promoters that if integrated within a transcriptional unit, could result in internal
initiation. If integration is in the sense orientation, then it can produce a truncated
transcript. Alternatively, integration in the antisense orientation (relative to the normal
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direction of transcription of the targeted gene) can result in inhibition of gene expression
by transcriptional interference. Expression of genes encoded by retrotransposons, such as
reverse transcriptase, are essential for their mobility and the DNA methylation of
retrotransposon promoters has been shown to silence their transcription (Kochanek, Renz
et al. 1995).
Evidence supporting the genome defense hypothesis comes from several sources.
Dnmtl homozygous knockout ES cells, which retain only 30% normal methylation
levels, have a ten-fold increase in the rate of mutations involving gene rearrangements
(Chen, Pettersson et al. 1998). These cells also show a large increase in transcription
from endogenous transposable elements (such as IAP elements) compared with wild-type
ES cells. More recently it has been shown that mice derived from ES cells carrying the
hypomorphic allele of Dnmtl (known as the ChiP allele) accumulate extensive
chromosomal rearrangements and retroviral insertions that ultimately result in cancer of
the thymus and premature death (Eden, Gaudet et al. 2003; Gaudet, Hodgson et al. 2003).
Similarly, human tumor cells often display global genome hypomethylation of parasitic
and repetitive DNAs, resulting in the re-expression of viral elements (Florl, Lower et al.
1999; Grassi, Girault et al. 1999). However conversely, human tumors often display a
region-specific gain of DNA methylation at CpG islands that occurs in conjunction with
the hypomethylation of repetitive DNA. The net outcome of these changes in the normal
DNA methylation pattern is a global alteration of gene transcription. When oncogenes
and tumor suppressors are affected in this way, the outcome is progression towards a
cancer phenotype (discussed further in section 1.2).
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1.1.1.3.2 Transcriptional repression
The connection between CpG methylation and transcriptional silencing has been
recognized for the past twenty years (Jones, Veenstra et al. 1998; Nan, Ng et al. 1998).
Although it was established that local cytosine methylation could directly interfere with
the binding of transcriptional activators, such a mechanism could not easily account for
more global silencing phenomena, such as X-chromosome inactivation.
The methyl-CpG binding proteins
Although DNA methylation is clearly repulsive to some DNA binding proteins, it
is singularly attractive to others. Early studies detected methyl-CpG binding activities
and implicated these as mediators of transcriptional repression (Hendrich and Bird 1998).
Progress in understanding the mechanism of repression came with the characterization of
MeCP2 and its relatives the methyl-CpG binding domain proteins MBD1-MBD4 (Lewis,
Meehan et al. 1992) (Hendrich and Bird 1998). Biochemical and transient transfection
studies identified a domain in each protein (except mammalian MBD3) that could target
it specifically to methylated CpG sites in vitro and in vivo (Hendrich and Bird 1998)
(Nan, Meehan et al. 1993).
Chromatin immunoprecipitation analyses have shown that MeCP2 and MBD2
associate with loci in a manner that is strictly dependent on DNA methylation (Billard,
Magdinier et al. 2002; El-Osta, Kantharidis et al. 2002; Rietveld, Caldenhoven et al.
2002). Studies with crude nuclear extracts support the notion that methyl-CpG binding
proteins, such as MeCp2 MBD2 and MBD1, function as transcriptional repressors
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because in their absence, methylated reporter genes are expressed (Boyes and Bird 1991).
A critical breakthrough in understanding how methylation-mediated repression worked
came from the finding that MeCP2 interacts with a co-repressor complex containing
histone deacetylases (HDACs) (Jones, Veenstra et al. 1998; Nan, Ng et al. 1998). MBD2
also associates with HDACs, extending a relationship between histone modification and
DNA methylation that is likely to be better understood in the future (Ng, Zhang et al.
1999; Feng and Zhang 2001).
Mbd2-null mice are viable and fertile, but lack the methylated DNA binding
complex MeCP1 (comprises MBD2 plus the NuRD chromatin remodeling complex) (Ng,
Zhang et al. 1999; Zhang, Ng et al. 1999; Hendrich, Guy et al. 2001). Cells deficient in
MBD2 exhibit significant de-repression of endogenous genes and are defective in the
methylated-mediated repression of transiently transfected genes. For example, MBD2
normally binds to the Interleukin-4 (14) gene and in Mbd2-1- mice, inappropriate
expression of 114 is found in a subset of naive T helper cells (Hutchins, Mullen et al.
2002).
The past decade has seen considerable progress in our understanding of how DNA
methylation is translated into functional states in the genome. The MBD family of
proteins has been identified that bind to methylated DNA and associate with enzymes
that alter the fundamental properties of chromatin. At a superficial level one could
attribute the functional properties of methylated DNA to these MBD associated proteins.
However, in contrast to the profound effects of loss of DNMTs, the consequences
of losing methyl-CpG binding proteins are much less severe. This discrepancy between
MBD and DNMT null animals may be caused by redundancy within the MBD family or
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alternatively other proteins that recognize DNA methyl marks may be involved. Recent
studies support the view that repression is multilayered and involves many collaborating
processes. If so, a combination of mutations in several methyl-CpG binding proteins
should produce a more severe phenotype (Wade 2001; Jaenisch and Bird 2003).
MeCP2 and Rett syndrome
In October 1999, it was announced that over 80% patients with the neurological
disorder Rett syndrome had mutations in the MeCP2 gene (Amir, Van den Veyver et al.
1999). Rett syndrome is an X-linked neurological disorder occurring in heterozygous
females that is characterized by normal early development, followed by a period of
regression. Patients lose speech and purposeful hand movements while acquiring a
variety of other neurological symptoms. Stabilization generally occurs and most patients
survive into adulthood (Rett 1966; Hagberg, Aicardi et al. 1983; Hagberg, Goutieres et al.
1985). The condition is almost always due to spontaneous mutations in MeCP2 that are
clustered in three regions: the methyl binding domain (MBD), the transcriptional
repression domain, or the C terminus. Notably, most missense mutations are tightly
concentrated in the MBD domain, leading to reduced binding of MeCP2 to methylated
DNA (Ballestar, Yusufzai et al. 2000). This suggests that binding to methyl-CpG is
essential for MeCP2 function.
Mice with null mutations in MeCP2 show phenotypic similarities to the human
condition that includes delayed onset of symptoms, small brain size, reduced dendritic
arborization, tremors, inertia, abnormal gait and arrhythmic breathing. Specific
inactivation of MeCP2 in the brain leads to the same phenotype as global deletion,
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emphasizing the neurological basis of Rett syndrome (Chen, Akbarian et al. 2001; Guy,
Hendrich et al. 2001; Shahbazian, Young et al. 2002).
On the basis of the genetic and biochemical properties of MeCP2, it has been
widely believed that the symptoms of Rett syndrome are due to a failure of effective
silencing of methylated genes. However, microarray analysis of brain transcripts from
wild-type and MeCP2 mutant mice has detected few if any gene expression differences
(Tudor, Akbarian et al. 2002). Thus, it is possible that MeCP2 has a function in the brain
that is not related to the repression of methylated genes. Alternatively, the absence of
one methyl-CpG binding protein may be so well compensated by other related proteins
that only subtle effects on gene expression occur, which are below detectable levels using
current technology.
1.1.2 Imprinting
The genetic non-equivalence of the mammalian maternal and paternal genomes
was uncovered by elegant pronuclear transplantation studies in the 1980s (McGrath and
Solter 1984; Surani, Barton et al. 1984). This surprising revelation forced classical
Mendelian genetics to undergo a number of revisions and led to the discovery of
imprinting, defined as the monoallelic expression of a gene in a parent-of-origin specific
manner. To date autosomal imprinting has only been demonstrated in eutherian
(placental) mammals. However, female marsupials exhibit a form of genomic imprinting
as they preferentially inactivate the paternal X chromosome in all somatic cells (Cooper,
Woolley et al. 1983). A similar mode of imprinted X inactivation occurs in the
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extraembryonic tissues of eutherian females and may represent the ancestral form of X
inactivation (Takagi and Sasaki 1975).
1.1.2.1 The function of imprinting in mammalian development
A question of central importance to the field is the functional significance of
genomic imprinting in mammals. The highly restricted developmental potential of
androgenotes with two paternal genomes and gynogenotes or parthenogenotes with two
maternal genomes was interpreted to mean that genomic imprinting was critical to
development of mammals. It should be noted that androgenotes and parthenogenotes do
not fail to imprint correctly or completely but rather have a genome-wide imbalance in
the dosage of imprinted genes. For example, the androgenotes will have double the
dosage of paternally expressed genes and no expression of maternally expressed genes.
The same condition holds for single or partial chromosomal uniparental disomies, which
have been extensively studied in mice, and often lead to developmental anomalies
(Reviewed in Surani 1994 and Latham, McGrath et al. 1995). This leaves open the
possibility that imprinting is dispensable under conditions where the imprints on both
parental genomes are erased (Jaenisch 1997). There is some indirect evidence for this,
parthenogenetic embryos that are generated from nuclei of immature oocytes at a stage in
development when imprints are not fully established develop to a later stage than
parthenogenotes from more mature oocytes whose imprints are in place (Kono, Obata et
al. 1996; Kono, Sotomaru et al. 2002).
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Figure 1.5 Mouse chromosome localization of imprinted genes
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Figure1.5 Mouse chromosome localization of imprinted genes.
Shows the distribution of imprinted genes in clusters on chromosomes throughout the mouse
genome. Imprinted genes that are maternally expressed are shown in red and imprinted genes
shown in blue are paternally expressed.
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In addition, adult mice have been cloned from migrating primordial germ cells at
different stages of migration demonstrating that partial erasure of the methylation
associated with imprinting is competent to support full development (Yamazaki, Low et
al. 2005). To determine the overall function of imprinting, studies of individual
imprinted genes have been made (Figure 1.5; Appendix 1). Of these genes, which now
numbers over 30, a trend has emerged where many of these genes fall into one of two
categories. Particularly striking is the number of imprinted genes whose protein directly
acts within the fetal growth pathway mediated by insulin like growth factor-2 (Igf2).
This includes Ig/2 itself and three genes that modulate its activity, the mannose-6-
phsophateIg2 receptor (Igf2r), GrblO and H19. Targeted mutations in each of these
genes confirm that these genes affect the rate of fetal growth (DeChiara, Efstratiadis et al.
1990; Filson, Louvi et al. 1993; Lau, Stewart et al. 1994; Leighton, Ingram et al. 1995).
In addition, a group of genes including p5 7 kip2, Gnas, Rasgrfl and Mash2 are involved in
regulating fetal overgrowth and/or cell cycle (Tilghman 1999). Unlike egg laying
animals, mammalian embryos develop in an almost parasitic-like manner and nutrients
that flow from the mother's placenta to the developing embryo must be regulated. So it
stands to reason that a new mechanism most be imposed to regulate embryonic growth as
failure to do so could be lethal to both mother and offspring.
Imprinting genes have recently been identified in a new role that is emerging in
the development of the brain. The first indications that this was likely came from human
behavior studies on children with Prader-Willi (PWS) and Angelman (AS) syndromes.
Both diseases are often caused by large megabase deletions at 15ql 1-q13, but in the case
of PWS, the deletion occurs on the paternal chromosome, whereas in AS, the affected
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chromosome is always of maternal origin (Lalande 1996; Nicholls, Saitoh et al. 1998).
Children with PWS are hypotonic, fail to suckle and develop obesity and mental
retardation with time. In addition they have short stature and small hands and feet. AS
patients are ataxic, hyperactive and much more severely retarded. Targeted deletions of
the syntenic chromosomal region in the mouse appear to recapitulate the phenotypic
characteristics of both diseases (Jiang, Armstrong et al. 1998; Yang, Adamson et al.
1998). These data suggest that PWS is caused by the loss of expression of multiple
paternal specific genes in this region, whereas AS may solely be due to the loss-of-
function of a single gene, Ube3a. Ube3a is imprinted exclusively in the brain and
encodes a ubiquitin ligase (Rougeulle, Glatt et al. 1997; Vu and Hoffman 1997).
Knowledge regarding the function of imprinting has been expanded through
chimera studies of androgenetic and pathenogenetic embryos. Overall, researchers
observed that androgenetic chimeras are oversized and exhibit striking muscle
hypertrophy. In contrast gynogenetic chimeras are growth retarded, consistent with a role
for imprinted genes in fetal growth. When cellular distribution studies were under-taken,
differences in the number and tissue contribution of uniparental cells in the brain were
found. Androgenetic cells inhibited overall brain size and contributed primarily to the
hypothalamus but not to the cortex. Gynogenetic cells appeared to enhance forebrain
growth and were more likely to contribute to the cortex, striatum and hippocampus
(Mann, Gadi et al. 1990; Allen, Logan et al. 1995; Keverne, Fundele et al. 1996).
Although these data come about as a result of imbalanced imprinting, where genes are
either over or under expressed, it is possible to hypothesize from this work that
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imprinting may have contributed over time to the rapid expansion of the cortex relative to
other parts of the brain.
Recent evidence has suggested that the role of imprinting in regulating embryonic
growth may extend into the next generation by influencing the maternal behavior.
Disruption of the imprinted gene Pegl, which is expressed broadly in the embryo but
restricted to the brain in adults, was shown to cause a general retardation of embryonic
growth. Surprisingly, the mutation in adult females is associated with poor maternal care,
including impaired placentophagia. Interestingly Pegl expression is high in the adult
hypothalamus, an organ that has been implicated in maternal behavior (Lefebvre, Viville
etal. 1998).
1.1.2.2 The evolution of genomic imprinting
Haig and colleagues suggested a theory for the evolution of imprinting by
drawing a connection between the growth effects displayed by mutations in some
imprinted genes and the behavioral effects in others. They proposed that imprinting will
arise in polyandrous animals as result of a conflict between males and females over the
allocation of maternal resources to offspring. Fathers will favor strategies for extracting
the maximal amount of resources for their offspring at the expense of the mother and her
future offspring by other sires. The mother counters this by using imprinting to allocate
resources equally among all her litter. This struggle results in a comprised growth rate,
leading to the suggestion that imprinting is a genetic 'tug-of-war' (Moore and Haig
1991).
31
According to Haig's model, paternally expressed genes should promote growth
and maternally expressed genes should negatively affect growth during the period where
the mother is solely responsible for the embryo's nutritional resources. This prediction
holds true for a number of imprinted genes (Appendix I), of which none had been
identified at the time of Haig's proposal. Some of the most striking examples include the
paternally expressed Ig/2 gene, a potent growth factor, that has a severe growth reduction
phenotype when disrupted in mice (DeChiara, Efstratiadis et al. 1990), and its maternally
expressed receptor Igf2r, in which mutations lead to oversized and nonviable embryos
(Filson, Louvi et al. 1993; Lau, Stewart et al. 1994; Wang, Fung et al. 1994). The Igf2r
protein is not involved in signal transduction but acts to sequester excess Igf2 and
transport it to lysosomes for destruction. The most convincing piece of data with respect
to the parental conflict model comes from the double mutant, which is normal-sized and
viable (Filson, Louvi et al. 1993). In addition to many imprinted genes being directly
involved in fetal growth, almost all are also imprinted in the placenta, a critical organ for
allocating maternal resources throughout embryogenesis (Tilghman 1999).
However there are a number of imprinted genes that do not fit into the parental
conflict model quite so neatly. For example, Pegl mutations affect both embryonic
growth and adult maternal behavior (rearing, nesting, and feeding behaviors). Although
this could be viewed as the father ensuring the expression of a gene in his daughters that
is beneficial to his grandchildren (Lefebvre, Viville et al. 1998), it is not immediately
apparent why the mother would choose to silence this gene, as they share a common
genetic interest in the offspring. Snrpn, which encodes a paternal specific protein that
functions in RNA processing and is located within the deletion found in PWS, represents
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another example. Snrpn is widely expressed in the embryo but contrary to what is
expected from the parental conflict model, targeted mutagenesis does not result in any
deleterious phenotype. However, a deletion in the promoter of Snrpn affects the
expression of a number of other paternally expressed imprinted genes located nearby. As
a result, the phenotype of the Snrpn promoter-deleted mice resembles PWS, including a
failure to suckle their young (Yang, Adamson et al. 1998). Thus, it is possible that
although Snrpn itself is not necessary for embryonic development, its imprinted
regulation may be required for the parental specific expression of neighboring genes
(Tilghman 1999).
Because the Haig hypothesis is based on the polyandrous nature of the first
mammals, it follows that imprinting should not be found in monogamous species, as both
parents have a common interest in all offspring so therefore there is no conflict. To test
the parental conflict model, imprinting was examined in the North American beach
mouse (Permyscus polionotus), a rare example of a monogamous mammal. Imprinting
was retained for the Igf2, Igf2r and HI 9 loci just as in the Mus musculus (Vrana, Guan et
al. 1998), thus one prediction of the parental conflict model was not met. However, this
finding needs to be interpreted carefully, as even limited partner exchange is sufficient to
induce parent offspring conflict. Indeed, partner exchange has been observed when P.
polionotus females have been captured on their own and then presented with new males
(Tilghman 1999). Interestingly, when these rodents are bred to the polyandrous
Peromyscus maniculatus, the hybrid offspring demonstrate significant disruption in
imprinting, suggesting that signals governing genomic imprinting are rapidly evolving
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and that disruptions in the process may contribute to mammalian speciation (Vrana, Guan
et al. 1998).
1.1.2.3 The establishment and erasure of the methylation mark in the germ line.
The study of the mechanism behind the establishment, erasure, and re-setting of
imprinting is a rapidly expanding field. A number of studies have shown the importance
of CpG methylation in maintaining the imprinted status of genes in the soma and it seems
likely that this would also be the case in the gamete (Reik, Dean et al. 2001). Consistent
with this, cis methylation marks are different in the egg and sperm and are maintained
during early embryogenesis when global methylation is lost (Tilghman 1999). More
definitive functional studies have confirmed the importance of these cis-acting elements
for the maintenance of imprinting by generating transgenic mice or targeted mutations
(Wutz, Smrzka et al. 1997; Thorvaldsen, Duran et al. 1998; Yang, Adamson et al. 1998).
The differentially methylated regions (DMRs) between different imprinted genes show
very little similarity, with the exception of the high density of CpG dinucleotides that are
necessary to maintain the methylation imprint. The mechanisms responsible for initiating
the methylation of DMRs are currently unknown.
Primordial germ cells (PGCs) are set aside very early during mouse embryonic
development, and up until E10.5 they are identical in both males and females. After this
stage of development, the methylation that maintains imprinting in PGCs is erased and
biallelic expression of imprinted genes can be detected (Brandeis, Kafri et al. 1993; Tada,
Tada et al. 1998; Davis, Yang et al. 2000; Ueda, Abe et al. 2000). How this occurs is as
of yet unclear, imprint methylation marks could be lost passively through the inhibition
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of Dnmtl and successive rounds of replication or by an active process of demethylation.
Indeed there is circumstantial evidence to suggest that both mechanisms might be
employed (Kafri, Gao et al. 1993; Rougier, Bourc'his et al. 1998) but no DNA
demethylase has been identified. A number of researchers have made use of germ cell
lines in culture that have been derived from PGCs at different stages of embryonic
development (known as embryonic germ (EG) cells). The study of EG cells overcomes
the problem of examining an extremely small population of cells but results should be
viewed with caution, as the process of culturing could induce epigenetic changes not
present in PGCs. Despite this, Tada and colleagues showed that EG cell lines derived
from E12.5 embryos contain an activity that could initiate demethylation of both
imprinted and non-imprinted DNA in nuclei of somatic cell hybrids, this finding is
consistent with the presence of either a demethylase or an inhibitor of Dnmtl in EG cells
(Tada, Tada et al. 1997).
After erasure, de novo methylation begins in both germ lines at the late fetal
stages and continues after birth (Kafri, Ariel et al. 1992; Brandeis, Kafri et al. 1993).
Oocytes are in meiotic arrest and methylation occurs during their growth (Obata,
Kaneko-Ishino et al. 1998), whereas during spermatogenesis, methylation occurs before
meiosis (Davis, Yang et al. 2000; Ueda, Abe et al. 2000). Nuclear transplant experiments
indicate that this DNA methylation coincides roughly with the acquisition of functional
imprints both for autosomal genes and for X chromosome imprinting (Obata, Kaneko-
Ishino et al. 1998; Tada, Obata et al. 2000). Thus far, evidence suggests that the
establishment of the methylation imprints is dependent on the expression of Dnmt3L,
which by itself has no detectable DNA methyltransferase activity but cooperates with the
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de novo methyltransferase DNMT3a to establish maternal imprints (Bourc'his, Xu et al.
2001; Hata, Okano et al. 2002).
1.1.2.4 Reading mechanisms for imprint gene silencing.
1.1.2.4.1 Short-range
Once imprints are introduced in the parental germlines, maintained in the early
embryo and then fully matured during differentiation, they need to be 'read'. This is
defined as a the conversion of methylation and chromatin codes into differential gene
expression, which at this point is thought to only take place at the level of transcription
(Jouvenot, Poirier et al. 1999). Generally, the 'reading' mechanisms of imprinted genes
are complex and often involve the regulation of more than one gene that is clustered in a
particular region. The reading mechanisms of DMRs described to date, fall into four
different categories: promoter sequences, overlapping antisense transcripts, boundary
elements and silencers. (Fig 1.6)
Promoter sequences.
Promoter regions are often rich in CpG regions, thus one of the commonest
mechanisms for achieving transcriptional silencing of one allele is by promoter
methylation. How a methylated promoter is transcriptional repressed is poorly
understood, although it is clear that methyl-binding proteins (MBPs) are able to form
complexes with histone deacetylases (Reik and Walter 2001). Thus, it is assumed that
MBP-HDAC complexes lead to a closed chromatin conformation that prevents
transcription factor access to the promoter (Bird and Wolffe 1999). Consistent with this,
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differences in specific patterns of histone methylation and acetylation have been
described between alleles of imprinted genes (Reik and Walter 2001).
Antisense Transcripts.
Regulation by antisense RNA is associated with a number of imprinted genes.
Thus far, all antisense transcripts associated with imprinted loci are themselves imprinted
and monoallelically expressed regardless of the parental expression of the imprinted gene
they regulate. Most of these antisense transcripts are noncoding and thought to have
some regulatory function (Reik and Walter 2001). Two of the best studied examples of
reciprocally-imprinted antisense transcripts are Air and Kcnqlotl, which overlap with the
maternally-expressed Igf2r and Kcnql genes, respectively (Lee, DeBaun et al. 1999;
Smilinich, Day et al. 1999; Lyle, Watanabe et al. 2000). Both of these antisense RNAs
originate in introns of the respective sense strand genes. The Air antisense transcript
includes some of the Igf2r promoter (Lyle, Watanabe et al. 2000), but this is not the case
for Kcnqlotl (Engemann, Strodicke et al. 2000). The promoter regions of the antisense
transcripts are CpG-rich and are differentially methylated on the inactive maternal allele.
Deletions of both of these DMRs leads to a loss of expression of the antisense transcript
and a loss of imprinting of Igf2r and Kcnql (Wutz, Smrzka et al. 1997) (Horike, Mitsuya
et al. 2000). The exact mechanism of how the antisense transcript interferes with the
expression of the sense gene is not known, but various scenarios could be envisioned
including the antisense transcript causing alterations to the chromatin structure, DNA
methylation, promoter exclusion or even RNA interference.
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Figure 1.6 Reading mechanisms in imprinted genes
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Figure 6 I Reading mechanisms in imprinted genes.
a I Differential silencing by CpG island or promoter methylation. b I Regulation by anti-
sense transcripts in conjunction with CpG island or promoter methylation; c I Allele-
specific regulation of neighbouring genes by dif-ferential methylation of boundary
elements within a CpG island. Factors such as CCCTC-binding factor (CTCF) (red disc)
bind to the unmethylated allele and block the access of upstream promoters to down-
stream enhancers (green), leading to transcriptional repression of the upstream gene. d
I Differential methylation results in differential binding of silencing factors (red, in this
case methylation-sensitive), which repress the promoter in cis. Adapted from Reik and
Walter 2001.
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It is also possible that the antisense transcripts have no role by themselves but instead
reflect the activity of other repressor sequences, such as silencers and boundary elements
(Reik and Walter 2001). This might explain how the deletion of the Kcnqlotl DMR
leads not only to the loss of repression of Kcnql, but also Cdknlc, a neighboring non-
overlapping imprinted gene (Horike, Mitsuya et al. 2000).
Boundaries
A recent observation that endoderm specific enhancers can be shared between the
physically linked genes IgJ2 (paternally expressed) and H19 (a maternally expressed non-
coding gene), suggests that chromatin boundaries might be involved in imprinted gene
regulation. The region upstream of H1 9 is paternally methylated and this is associated
with expression of the neighbouring Ig/ 2 gene. When this region in deleted from the
maternal allele, the normally silent Igf2 gene is expressed (Thorvaldsen, Duran et al.
1998). This led to the model that the DMR associated with H19 is a chromatin boundary
element that is in a 'closed' state when unmethylated but is in an 'open' state when
methylated. Several DNaseI hypersensitive sites have been found on the unmethylated
maternal H1 9 DMR region and these are not present on the methylated paternal allele
(Hark and Tilghman 1998; Khosla, Aitchison et al. 1999). In addition, the previously
characterized chromatin boundary element CTCF, which has been shown to be important
for the function of the chick globin gene boundary element, binds to the maternal but not
to the paternal H19 DMR (Bell and Felsenfeld 2000) (Hark, Schoenherr et al. 2000;
Kanduri, Pant et al. 2000; Szabo, Tang et al. 2000). Furthermore, deletion studies have
shown that loss of the CTCF-binding motifs in the H19 DMR abolishes the observed
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boundary effect (Bell and Felsenfeld 2000) (Hark, Schoenherr et al. 2000; Kanduri, Pant
et al. 2000; Szabo, Tang et al. 2000).
Silencers or enhancer competition.
A number of imprinted genes have DMRs associated with the expressed allele and
this has led to the suggestion that these regions contain silencers (ie elements bound by
repressors) that are inactivated by methylation (Sasaki, Jones et al. 1992; Brandeis, Kafri
et al. 1993; Stoger, Kubicka et al. 1993; Feil, Walter et al. 1994). This model has proved
correct for the DMR1 of the Ig2 gene, which is paternally expressed and methylated in a
number of fetal tissues such as the heart, kidney and lung. The Ig/2 DMR1 functions as
a maternal silencer in a subset of these tissues, as its deletion in mice results in repression
of expression (Constancia, Dean et al. 2000).
1.1.2.4.2 Long range or imprint control regions.
The existence of imprint control regions (ICRs) was first proposed following
molecular and genetic studies of imprinting disorders and targeted mutagenesis analyses
in mice (Buiting, Saitoh et al. 1995; Leighton, Ingram et al. 1995; Yang, Adamson et al.
1998). It was observed that the expression of certain imprinted genes is dependent upon
a signal that acts over large distances. Patients with the imprinting disorder PWS have
small microdeletions of the promoter and the first exon of the SNRPN gene, which results
in the loss of expression of not only SNRPN, but at least three other paternally-expressed
genes that lie on the same chromosome. Similarly, AS patients were found to have
deletions a few kilobases upstream of where the PWS microdeletions are found. For
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presentation of the disease phenotype, paternal transmission of the deletion is required for
PWS, whereas AS requires maternal transmission. The ability of these deletions to alter
the expression and methylation patterns of multiple imprinted genes that lie as far away
as 1 megabase, is referred to as 'epigenotype spreading' (Buiting, Saitoh et al. 1995). In
the PWS patients, these genes (which are normally paternally-expressed) are found
silenced and methylated. Correspondingly, in AS patients, maternal transmission of the
deletion results in the expression and demethylation of genes that are otherwise
repressed. These results have been recapitulated in the mouse model of the PWS deletion
(Yang, Adamson et al. 1998). Based on these observations it has been proposed that the
ICR region functions to switch the regional epigenotype in the germline (i.e. in PGCs
during embryogenesis) or alternatively, it plays a role in the maintenance of the
epigenotype (Reik and Walter 2001). However, at this point it is still unknown whether
epigenotype spreading occurs in the germline or postzygotically. In addition, little is
known about the factors that mediate this phenomenon.
1.2 Cancer biology
1.2.1 DNA methylation and cancer
Over the last five years it has become clear that the traditional model of cancer
initiation and progression, involving multiple changes in chromosomal instability,
activation of oncogenes, silencing of tumor suppressors and the inactivation of DNA
repair machinery, is not only caused by genetic mutations but also by epigenetic
abnormalities (Feinberg and Tycko 2004). During cancer progression, it has been noted
that the genome undergoes both global hypomethylation and regional hypermethylation
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at CpG islands (Feinberg and Tycko 2004). Alteration to the methylation state of the
genome can eventually have both genetic and epigenetic consequences for the cell and
carcinogenesis.
1.2.1.1 Hypomethylation
A large body of evidence now exists to show that hypomethylation of DNA leads
to the activation of otherwise silent genes (Feinberg and Vogelstein 1983). CpG islands
that are known to be methylated in somatic tissues have recently been shown to be
hypomethylated in cancer, causing the activation of nearby genes (Strichman-Almashanu,
Lee et al. 2002). Examples of genes that are affected by promoter CpG demethylation
include the oncogene H-Ras (Feinberg and Vogelstein 1983), Cyclin D2 (Oshimo,
Nakayama et al. 2003), maspin in gastric carcinoma (Akiyama, Maesawa et al. 2003),
CA9 in human renal-cell carcinoma and human papillomavirus 16 (HPV16) in cervical
cancer (Badal, Chuang et al. 2003).
Recently, DNA hypomethylation has been shown to cause genomic instability.
This link was made when Wilm's tumors, ovarian and breast carcinomas were found to
have significant demethylation within the pericentric region of satellite repeat sequences
(Qu, Grundy et al. 1999). This demethylation is frequently associated with unbalanced
chromosomal translocations with the breakpoint occurring in the pericentric regions of
chromosome 1 and 16 (Qu, Grundy et al. 1999). These unbalanced translocations are
often the only detectable abnormality found and result in loss-of-heterzygosity (LOH) for
chromosome 16 and a characteristic anaplasia (Yeh, Wei et al. 2002).
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The most direct evidence for genomic instability due to hypomethylation has
come from the study of cells that express very low levels of Dnmtl. DNA
hypomethylation caused by an insufficiency of Dnmtl leads to increased mitotic
recombination and LOH due to chromosomal translocations (Eden, Gaudet et al. 2003;
Gaudet, Hodgson et al. 2003). It should be noted however, that a transgene in
hypomethylated ES cells showed no evidence of LOH. This discrepancy could be due to
the chromosomal location of the transgene and/or the differentiation state of the cell
(Chan, van Amerongen et al. 2001).
1.2.1.2 Hypermethylation
As discussed earlier, DNA methylation at CpG islands is believed to be the major
mechanism for maintaining the silent epigenetic state. In support of this, demethylating
drugs result in the reactivation of silenced genes. The role of hypermethylation in cancer
progression was pioneered with studies relating to the classic tumor-suppressor
retinoblastoma (RB) gene. The Horsthemke study in the 1989 showed that the RB
promoter is methylated in a significant number of retinoblastomas (Greger, Passarge et al.
1989). The magnitude of this epigenetic silencing was appreciated when it was
demonstrated that there was a 92% reduction of RB expression in tumors with promoter
hypermethylation (Ohtani-Fujita, Fujita et al. 1993; Greger, Debus et al. 1994). More
recent studies have confirmed promoter hypermethylation at numerous other loci in
cancer cells supporting the notion that epigenetic gene inactivation contributes to cancer
progression. Key tumor suppressor proteins such as p16 k4a, MLH1, VHL and E-
cadherin were all shown to be eliminated in both cell lines and in primary cancers by an
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epigenetic pathway that correlates with dense CpG methylation of their respective
promoters (Herman, Latif et al. 1994; Gonzalez-Zulueta, Bender et al. 1995; Graff,
Herman et al. 1995; Cunningham, Christensen et al. 1998).
1.2.1.3 Loss of imprinting
Evidence for a role of human imprinted genes in cancer formation came in the
1980s when several independent studies reported a strong parent-of-origin bias in LOH
for chromosome lp 15 alleles in Wilm's tumor and rhabdomyosarcoma. The finding
that there was consistently a loss of maternal alleles and a duplication of paternal alleles,
led to the suggestion that loss of imprinting (LOI) was the likely cause (Schroeder, Chao
et al. 1987; Pal, Wadey et al. 1990) (Scrable, Cavenee et al. 1989; Williams, Brown et al.
1989). In addition, studies of familial Beckwith-Widemann Syndrome (BWS), which
causes prenatal overgrowth and leads to a predisposition of various embryonal tumors
including Wilm's tumor (Brown, Williams et al. 1990), also indicated a parent-of-origin
effect, as the overgrowth phenotype was only seen after maternal transfer (Brown,
Williams et al. 1990). More direct evidence came from mapping BWS to lp 15 and the
demonstration that chromosomal rearrangements in this region in patients with BWS
were all of maternal origin (Mannens, Hoovers et al. 1994). More recent cancer studies
have focused on LOI at single loci, including Ig/2, Igf2r and Peg3.
1.2.1.3.1 Insulin-like growth factor-2
LOI leading to biallelic expression of IGF2 in Wilm's tumors was discovered in
the early 1990s (Ogawa, Eccles et al. 1993; Rainier, Johnson et al. 1993). Additional
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studies demonstrated that this abnormality was always linked to a gain of DNA
methylation in the closely linked H19 gene (Moulton, Crenshaw et al. 1994; Steenman,
Rainier et al. 1994). Overexpression of Ig/2 is known to induce growth, however recent
work has suggested that the mechanism of tumor progression may actually be due to an
inhibition of apoptosis. Hanahan and colleagues found that knocking out one allele of
Igf2, which prevents biallelic expression, arrested cancer progression in a B-lymphocyte
tumor model by increasing apoptosis (Christofori, Naik et al. 1994; Christofori, Naik et
al. 1995). n more recent mouse studies, it was shown that the number of intestinal
tumors that form in Apc+/min mutant mice was increased when Ig/2 was biallelically
expressed (Sakatani, Kaneda et al. 2005). Taken together, these studies suggest that a
loss of normal imprinting at the Igf2/H19 locus contributes to cancer progression.
1.2.1.3.2 Insulin-like growth factor-2 receptor and peg3
The mannose 6 phosphate/insulin-like growth receptor (Igf2r) is an intriguing
protein with multiple ligands and multiple functions. Approximately 90-95% of the
receptor is located intracellularly, with 5-10% being on the cell surface. It is known to be
essential for the transport of newly-synthsized lysosomal enzymes from the trans-golgi
network to the lysosomes. More recently however, the loss of this receptor has been
described in some tumor types. Jirtle and colleagues have clearly demonstrated LOI and
LOH at the Igf2r locus in breast, lung and liver tumors (De Souza, Hankins et al. 1995;
De Souza, Hankins et al. 1995; Hankins, De Souza et al. 1996; Yamada, De Souza et al.
1997; Kong, Anscher et al. 2000). However, not all tissues display a loss of Igf2r
45
following cancer transformation, raising the possibility that in these tumors, Ig2r
expression confers a selective advantage.
Peg3 is a paternally imprinted gene that encodes a protein with 12 C2H2 Kruppel-
like zinc fingers and two proline-rich repeat domains (Kuroiwa, Kaneko-Ishino et al.
1996; Relaix, Weng et al. 1996). Peg3 physically interacts with tumor necrosis factor
(TNF)-receptor-associated factor 2 (TRAF2), which is involved in the TNF-nuclear
factor pathway (Relaix, Wei et al. 1998) and mediates apoptosis via p53 (Relaix, Wei et
al. 2000). Peg3-deficient mice are viable, albeit smaller than their wild-type siblings, and
adult female mutants display impaired maternal behaviors such as nest building,
gathering pups and keeping them warm (Li, Keverne et al. 1999). Interestingly, PEG3
maps to 19q13.4, a region that contains a putative tumor suppressor of
oligodendrogliomas (Maegawa, Yoshioka et al. 2001; Sanson, Leuraud et al. 2002).
Consistent with this, PEG3 has tumor suppressor activity in transfected cells and is
epigenetically silenced in gliomas (Kohda, Asai et al. 2001) (Maegawa, Yoshioka et al.
2001).
1.2.2 Genetic mechanisms of cancer.
The cancer phenotype is characterized by a number of features. Compared with
many normal tissues, cancer cells are highly sensitized to apoptotic signals and survive
only because they have acquired lesions that prevent or impede cell death. Cancers are
also able to invade and colonize the surrounding tissues. By comparing cells that are
derived from cancer patients with those from normal individuals and by utilizing mouse
46
models of key cancer regulators, it has been possible to gain significant insights into the
molecular and cellular nature of the cancer phenotype.
1.2.2.1 DNA repair, cell-cycle checkpoints and cancer.
DNA-repair and cell-cycle checkpoint pathways allow cells to deal with both
endogenous and exogenous sources of DNA damage. In addition to directly repairing
DNA breaks or adducts, cells respond to DNA damage by halting cell-cycle progression
or by undergoing programmed cell death. How much an individual is exposed to these
agents and how their cells respond to DNA damage are critical determinants of whether
that individual will go on to develop cancer.
1.2.2.1.1 DNA Repair
The DNA contained in every mammalian cell is under constant attack by agents
that can either directly damage one of its three billion bases or break the phosphodiester
backbone on which the base resides. Because there are various types of DNA lesions that
can occur, a variety of different repair mechanisms exist to combat the damage.
DNA can be damaged in at least three ways. Firstly, energy by free oxygen
radicals can break the phosphodiester bonds in the backbone of the DNA helix. When
two of these are close to each other but on the opposite strand, a double-strand break
(DSB) is present in the DNA and the cell faces a challenging repair (Doll and Peto 1981).
Secondly, alkylating chemical moieties can modify purine bases and thirdly, inhibitors of
DNA topoisomerases can lead to enhanced single or DSBs depending on which
topoisomerase is inhibited and on the phase of the cell cycle (Froelich-Ammon and
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Osheroff 1995). Different mechanisms are required to repair the damage to the DNA
backbone or to the DNA bases, and the challenges of repairing the DNA can vary in the
different phases of the cell cycle. To optimally repair DNA damage, the cell must also
control other cellular processes before or during the repair, such as DNA replication or
mitosis. Cells that are damaged when they are in the middle of the process of DNA
replication face this challenge by halting or slowing replication until the damage has been
repaired (Kastan and Bartek 2004).
The first steps leading to an inhibition of the cell-cycle following DNA damage
include activation of the phosphatidyl-inositol-3-OH kinase-like kinases (PIKKs), ATM
(ataxia telangiectasia mutated) and ATR (ATM and Rad3 related). The ATM kinase is
primarily activated following DNA damage, whereas the ATR kinase seems to be critical
for mediating the cellular response to an arrest in DNA replication-fork progression
(caused by DNA damage or other stresses). Due to the many types of lesions that can
result from direct DNA damage and from an arrest of DNA replication forks, ATM and
ATR seem to participate together in many cellular-stress responses (Abraham 2001;
Shiloh and Kastan 2001).
To efficiently transduce the alert signal and initiate a global cellular response to
DNA damage, proximal checkpoint kinases ATM and ATR cooperate closely with two
other classes of proteins, the checkpoint mediator (or adaptor) proteins and the transducer
kinases CHK1 and CHK2 (Bartek and Lukas 2003; Shiloh 2003).
The study of checkpoint mediators is an emerging field, with the precise
mechanism of action largely unknown. Thus far, there are three mediator checkpoint
factors (MDC1, 53BP1 and BRCA1) involved in facilitating the signaling of ATM and
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one protein, claspin known to modulate ATR (DiTullio, Mochan et al. 2002; Wang,
Matsuoka et al. 2002; Goldberg, Stucki et al. 2003; Lou, Minter-Dykhouse et al. 2003;
Manke, Lowery et al. 2003; Shang, Bodero et al. 2003; Yu, Chini et al. 2003; Chini and
Chen 2004). As most of the mediators are initially recruited to the site of DNA damage
independently of ATM and ATR, they might be involved in identifying these lesions or
recruited through their interaction with candidate DNA-damage sensors (Goldberg,
Stucki et al. 2003; Kastan and Bartek 2004).
The transducing kinases CHK1 and CHK2 are activated by ATM and ATR
phosphorylation and in turn regulate downstream checkpoint targets, affecting the
machinery involved in DNA repair, apoptosis and the cell cycle (Bartek and Lukas 2003).
Most prominent among their targets, tanscription factor p53 and the family of the
cyclin/CDK activator proteins CDC25 (Bartek and Lukas 2003).
1.2.2.1.2 Cell cycle checkpoints
There are four successive phases of a typical mammalian cell cycle: M phase
consists of nuclear division followed by cytoplasmic division, after which the daughter
cells begin interphase of a new cell cycle. Interphase starts with the G1 phase in which
biosynthetic activities resume after cellular division. The S phase begins when DNA
synthesis starts and ends when the DNA content of the nucleus has doubled, resulting in
chromosome replication. The cell then enters G2 phase with continued biosynthetic
activities until mitosis starts initiating M phase.
During unperturbed proliferation, a mammalian cell can only withdraw from the
cell-cycle in the early- to mid-G1 phase in response to growth-factor deprivation or
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growth inhibitory signals. This must occur before the cell passes through a restriction
point controlled by the transcription factors retinoblastoma (RB) and E2F. After this
point, the cell is committed to a round of DNA replication and cell division. Given the
critical significance of error-free DNA replication and chromosome segregation for the
maintenance of genomic integrity and the prevention of cancer, it is not surprising that
these stages of the cell cycle are protected by a number of check-point effector
mechanisms (Bartek, Bartkova et al. 1997; Sherr and McCormick 2002).
The dominant checkpoint response to DNA damage in the G1 phase of the cell
cycle is the ATM/CHK2-p53/p21ciPl pathway, which is capable of inducing sustained
and sometimes permanent G1 arrest (Kastan, Lim et al. 2000; Bartek and Lukas 2003).
The intra-S-phase checkpoint network, which is activated by genotoxic insults, causes
largely transient, reversible inhibition of the DNA origins-of-replication that have not yet
been initiated. There are two parallel branches of this checkpoint that slow down the
ongoing DNA synthesis, both of which are controlled by the ATM/ATR signaling
machinery (Bartek and Lukas 2003; Bartek, Lukas et al. 2004). Finally, the G2
checkpoint prevents cells from initiating mitosis when they experience DNA damage
during G2, or when they progress into G2 with some unrepaired damage inflicted during
the previous S or G1 phases (Nyberg, Michelson et al. 2002; Xu, Kim et al. 2002). The
critical target of the G2 checkpoint is the mitosis promoting activity of the cyclin
B/CDK1 kinase. CyclinB/CDK1 activation is inhibited after various stresses by
ATM/ATR, CHK1/CHK2 and the inactivation of the CDC25 family of phosphatases,
responsible for activating CDK1 (Smits and Medema 2001).
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1.2.2.2 Key tumor suppressors and their role in the cell cycle.
The proteins p53, Rb, p16Ink4 a, p19Arf and p21cPl reside at the core of a signaling
network that principally governs cell-cycle entry and exit. Loss-of-function ofpl 6 nk4a" ,
p9 A'rf Rb and p53 occurs frequently in cancers, prompting speculation that biochemical
pathways regulated by these proteins must be disabled in order for normal cells to be
transformed into tumor cells (Fig 1.7).
1.2.2.2.1 Tumor suppressor p53.
The p53 tumor suppressor belongs to a small family of structurally and
functionally related proteins that includes two other members p63 and p73 (Melino, De
Laurenzi et al. 2002). Whereas p63 and p73 play important roles in embryonic
development (Irwin and Kaelin 2001), p5 3 has evolved in higher organisms to prevent
tumor development. Activation of p53 occurs in response to several malignancy-
associated stress signals, resulting in the inhibition of cell growth (Balint and Vousden
2001). Several cellular responses can be invoked by p53, including cell-cycle arrest,
senescence, differentiation and apoptosis, with the option chosen dependent on many
factors that are both intrinsic and extrinsic to the cell (Vousden and Lu 2002). Under
some circumstances, p53 also contributes to the repair of genotoxic damage, potentially
allowing for the release of the rehabilitated cell back into the proliferating pool.
However, in most cases induction of p53 leads to an irreversible inhibition of cell growth,
most decisively by activating apoptosis.
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Mutations of the p53 gene
Loss of p53 function in cancer can occur by a number of mechanisms, including
lesions that prevent induction of p53, mutations within the gene itself or mutations in the
downstream targets of p53 (Harris and Levine 2005). Analyses of many tumors have
shown that p53 is mutated in about half of all cancers, resulting in a loss of apoptotic
function. Tumor-associated mutations in p53 are predominantly point mutations that
result in single amino-acid substitutions. The mutational spectrum seen in p53 is very
different from other tumor suppressor genes in which large deletions or frame-shift
mutations tend to result in the complete loss of protein expression (Vousden and Lu
2002). The result of p53 mutation by single amino acid substitutions is that many tumor
cells retain the ability to express the mutant p53 protein. These point mutant proteins are
often more stable than wild-type p53 and levels accumulate at very high levels in the
tumor cell. One explanation for the selection of such mutations is that the mutant p53
proteins can act as dominant-negative inhibitors of wild-type p53, which functions as a
tetramer (Ko and Prives 1996; de Vries, Flores et al. 2002; Olive, Tuveson et al. 2004).
In addition to the dominant-negative inactivation of wild-type p53, there is evidence that
some of the tumor associated mutant p53 proteins acquire new transforming functions
that contribute to tumor development (Sigal and Rotter 2000).
Mutations in regulators of p53 and downstream targets
Human tumors that do not display mutations in p53 frequently harbor defects in
either the pathways that allow for the stabilization of p53 in response to stress, or in the
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effectors of the apoptotic activity of p53 (Woods and Vousden 2001). Two related
proteins, MDM2 and MDM4, have critical roles in regulating p53 activity (Jones, Roe et
al. 1995; Montes de Oca Luna, Wagner et al. 1995; Parant, Chavez-Reyes et al. 2001).
MDM2 participates in an autoregulatory loop with p53 and functions as an ubiquitin
ligase that targets p53 for degradation. Defects in pathways that inhibit MDM2 activity
are common in tumors that do not possess mutations in the p53 gene (Vousden 2002).
Apoptotic activities ofp53
p53 is a transcription factor that activates the expression of genes that contain
p53-binding sites within their regulatory regions and a number of target genes have been
identified (Vousden and Lu 2002). Many of these genes can be divided into classes that
might mediate a specific p53 function, one of the largest of these groups are those genes
involved in the activation of apoptosis. p53 can induce the expression of numerous
apoptotic genes that can contribute to the activation of both death-receptor and
mitochondrial apoptotic pathways. In addition, p53 can also affect the efficiency of
survival signaling (Vousden and Lu 2002).
Identification of pro-apoptotic transcriptional p53 targets revealed several
members of the Bcl-2 family (Bax, Puma, Noxa and Bid) as the best gene targets for
triggering the mitochondrial pro-apoptotic pathway inducing the release of Cytochrome-c
and the eventual activation of Caspase-3 (reviewed in Schuler and Green 2005). In
addition, members of the apoptotic death receptor pathway, Fas, Pidd and Killer/Dr5
were also up regulated in response to p53, ultimately activating the same effector
Caspase-3 resulting in cellular apoptosis (reviewed in Ozoren and El-Deiry 2003).
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In addition to the mitochondrial and death receptor apoptotic pathways the choice
between cell death and survival is strongly dependent on the activity of 'survival signals'
such as soluble ligand binding or direct interaction with neighboring cells or the
extracellular matrix(Vousden and Lu 2002). p53-induced apoptosis can be rescued by
the activation of Akt kinase which is able to interact with and stabilize Mdm2, enhancing
the degradation of p53(Sabbatini and McCormick 1999). Furthermore, through indirect
evidence it is thought that Akt may down regulate the expression of Puma, which as
discussed earlier is a mediator of the apoptotic response through the mitochondrial
pathway (Han, Flemington et al. 2001). Interestingly, the inhibition of p53 by Akt is
counteracted by the ability of p53 to induce expression of Pten, a phosphatase that can
inhibit the activation of Akt (Stambolic, MacPherson et al. 2001). The induction of Pten
has been shown to be essential for p53 mediated apoptosis in mouse cells, underscoring
the importance of survival signaling in determining the final outcome of the p53
response.
The ability to engage various apoptotic pathways via several routes is likely to be
particularly important for the tumor-suppressor activity of p53, as the selective pressure
to lose pro-apoptotic gene function is extremely high during tumor development.
1.2.2.2.2 The retinoblastoma protein
Retinoblastoma is a rare childhood cancer of the retina that initiates during
development as a result of RB inactivation in the developing retina. RB encodes a 110-
kDa nuclear phosphoprotein that binds and inhibits members of the E2F transcription
factor family. E2F transcription factors regulate other genes required for S-phase and cell
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cycle progression (Classon and Harlow 2002). The binding of RB to E2F is regulated by
the phosphorylation of cyclin/cyclin-dependent kinases. RB acts as a tumor suppressor,
in part, by inhibiting cell-cycle progression past the G1/S restriction point. Inactivation
of RB removes the constraint on cell-cycle control, which results in deregulated cell
proliferation. Two other RB family members have been identified, p107 and p130 (also
known as retinoblastoma-like and retinoblastoma-like 2, respectively). These proteins
have functions in common with RB, but also possess unique functions (Classon and
Dyson 2001).
1.2.2.2.3 p194rf and p16nk4a
The Ink4a-Arf locus encodes two tumor suppressors, Ink4a (p16 nk4a) and Arf
(p 9 A f in mice and p 14Arf in humans) whose expression enhances the growth-suppressive
functions of Rb and p53, respectively. The genetic organization of the Ink4a-Arf locus is
unusual because the two protein products are encoded in part by common nucleotide
sequences that are read in alternative reading frames (Sherr 2001). Activation of p 6 "k4a
andp9 Arf is commonly associated with cellular senescence-- a form of cell-cycle arrest
that is thought to be irreversible and was initially linked to the replicative exhaustion of
human fibroblasts in culture. Although replicative senescence is triggered by telomere
malfunction, a phenotypically similar endpoint can be produced much more rapidly in
response to activated oncogenes, DNA damage, oxidative stress and inappropriate cell-
culture conditions (Shay and Wright 2001).
The pl9A rf protein binds directly to, and inactivates, Mdm2, and this is turn
triggers a p53-dependent transcriptional program that leads either to GI1-phase arrest or to
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apoptosis. The pl9 Arf protein accumulates in the nucleolus of cells and can mobilize
Mdm2 to this compartment, segregating Mdm2 from p53. p19a rf binding to Mdm2 also
antagonizes its E3 ubiquitin ligase activity for p53, thereby preventing p53 turnover
(Sherr 2001).
E2F transcription factors regulate genes that promote entry into the S-phase of the
cell-cycle. By binding to E2Fs on chromatin, Rb-family members (Rb, p107 and p130)
recruit histone deacetylases and chromatin remodeling factors to E2F-responsive
promoters to repress gene expression. Phosphorylation of Rb by cyclin D- and cyclin E-
dependent kinases (Cdks), releases E2Fs from the negative constraints of Rb, enabling
execution of the E2F transcriptional program. In turn, p1 6 Ink4a can inhibit cyclin D-
dependent kinases, thereby maintaining Rb-E2F repression and restricting cell
proliferation (Sherr 2001)
1.2.2.2.4 Cdk interacting protein p21 (p21CiP1)
p21ciPl is a well-characterized cyclin-dependent kinase (cdk) inhibitor that
belongs to the Cip/Kip family of cdk inhibitors (Gartel, Serfas et al. 1996). It mainly
inhibits the activity of cyclin/cdk2 complexes and negatively modulates cell cycle
progression (Brugarolas, Moberg et al. 1999). In addition, p2 1Cipl can bind to
proliferating cell nuclear antigen thereby blocking DNA synthesis (Waga, Hannon et al.
1994).
p21Cipl is a transcriptional target of p53 and plays a crucial role in mediating
growth arrest when cells are exposed to DNA damaging agents such as doxorubicin and
(Brugarolas, Moberg et al.) gamma irradiation (el-Deiry, Harper et al. 1994; el-Deiry,
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Tokino et a. 1995). It has been shown that overexpression of p21Cipl results in GI-, G2-,
or S-phase arrest (Ogryzko, Wong et al. 1997; Radhakrishnan, Feliciano et al. 2004).
Conversely, p21CiPl-deficient cells fail to undergo cell cycle arrest in response to p53
activation after DNA damage (Waldman, Kinzler et al. 1995). Furthermore, p21 CiP and
p53 are essential to sustain the G2 checkpoint after DNA damage in human cells (Bunz,
Dutriaux et al. 1998).
Apart from p53, a variety of other factors including Spl/Sp3, Smads, Ap2, signal
transducers and activators of transcription (STAT), BRCA 1, E2F- 1 /E2F-3, and
CAAT/enhancer binding protein (Cooper, Woolley et al.) are known to activate p21Cipl
transcription (reviewed in Gartel and Tyner 1999). In addition to its role in DNA damage
response, p21 Cip1 is also implicated in terminal differentiation, replicative senescence, and
protection from p53-dependent and -independent apoptosis (reviewed in Gartel and Tyner
2002).
1.2.2.3 Tumorigenesis
The process of malignant transformation occurs in discrete histopathological
steps, many of which correlate with specific genetic alterations. After the experiments of
the 1980s, it became clear that a single mutation was rarely, if ever, sufficient to
accomplish the entire process of transformation. Subsequent studies using transgenic
mice showed that pairs of oncogenes, that were capable of collaborating to immortalize
and then transform cells in vitro, could drive tumor formation with far more rapid
kinetics than single oncogenes (Land, Parada et al. 1983; Ruley 1983; Sinn, Muller et al.
1987; Thompson, Southgate et al. 1989). It is now clear that there are a limited number
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of molecular pathways that when disrupted, contribute to most, if not all cancers. In
humans, colon cancer studies suggest that 4-6 mutations are required to reach this state,
but fewer seem to be required in mice (Hahn and Weinberg 2002).
1.2.2.3.1 Immortalization of human and mouse cells
Most normal human cells are mortal, lack telomerase activity and show telomere
shortening with passage in culture. By contrast, most cells that are derived from human
cancer patients are immortal, express telomerase and have stable telomere lengths. In
vitro experiments with human cells demonstrate that they have limited replication
lifespan and enter irreversible growth arrest after extended passage, termed replicative
senescence (Hayflick and Moorhead 1961). Introduction of viral oncogenes, such as
SV40 Large T antigen (LgT antigen), bypasses senescence but the cells remain mortal
(Shay, Pereira-Smith et al. 1991; Bond, Haughton et al. 1999). LgT antigen acts by
binding to, and inactivating, Rb and p53 (Rundell and Parakati 2001). The continued
passage of LgT-expressing post-senescent cells results in a second barrier being reached,
termed crisis, which is characterized by widespread apoptosis and genome-wide
instability caused by shortened telomeres (Counter, Avilion et al. 1992; Sedivy 1998).
However, activation of telomerase or its catalytic domain hTERT will immortalize post-
senescent human cells (Bodnar, Ouellette et al. 1998; Vaziri and Benchimol 1998; Yang,
Chang et al. 1999). An accumulation of work now exists to indicate that three pathways
involving: telomere shortening, p53 and Rb control replicative senescence and
immortality in humans, and play a central role in almost all cancers (Hahn and Weinberg
2002).
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In contrast to human cells, studies with mouse embryo fibroblasts (MEFs) have
shown that genetic inactivation of either p1 9Arf orp53 alone is sufficient for cellular
immortalization (Zindy, Eischen et al. 1998) (Harvey and Levine 1991; Kamijo, Zindy et
al. 1997). As primary MEFs are grown in culture they eventually undergo growth arrest,
in which levels of p19A r f (and therefore p53) are elevated (Zindy, Eischen et al. 1998).
The spontaneous inactivation of either of these genes allows the outgrowth of clones of
immortalized MEFs (Harvey and Levine 1991; Kamijo, Zindy et al. 1997). Current
research does not indicate that telomere shortening plays a role in limiting the cellular
lifespan of cells derived from inbred mice. Despite this difference with human cells,
mouse models have provided essential insights into the biology of human cancer and
continue to be an invaluable tool to understand the mechanisms of tumorigenesis.
1.2.3 Perspectives on cancer biology
Our understanding of the molecular basis for cancer formation has rapidly
advanced in the last 20 years. Emerging from a seemingly impenetrable thicket of
genetic complexity has come the realization that, for most part, all cancers are controlled
by a common set of mechanisms. However, cancer biologists are facing a new era in
which they must unite with the field of epigenetics, a discipline that has long been in the
shadows of human cancer genetics. It is now clear that the epigenetic mechanisms that
control hypomethylation, hypermethylation, and LOI play a significant role in tumor
progression (Feinberg and Tycko 2004). Thus, integrating the epigenetics of
tumorigenesis into the mainstream of cancer biology will be one of next challenges for
the field.
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2.1 Abstract
Loss of imprinting (LOI), commonly observed in human tumors, refers to loss of
monoallelic gene regulation normally conferred by parent-of-origin specific DNA
methylation. To test the function of LOI in tumorigenesis, we developed a model using
transient demethylation to generate imprint-free mouse embryonic stem cells (IF-ES
cells). Embryonic fibroblasts derived from IF-ES cells (IF-MEFs) display
TGF[3 resistance, reduced p1 9Arf and p53 expression, and form tumors in SCID mice. IF-
MEFs exhibit spontaneous immortalization, and cooperate with H-ras in cellular
transformation. Chimeric animals derived from IF-ES cells develop multiple tumors
arising from the injected IF-ES cells within 12 months. These data demonstrate LOI
alone can predispose cells to tumorigenesis, and identify a pathway through which
immortality conferred by LOI lowers the threshold for transformation.
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2.3 Introduction.
Cancer has traditionally been thought to be caused by a series of genetic
mutations in cancer-susceptibility genes, which include oncogenes, tumor-suppressor
genes and genes causing genetic instability. Until recently, this rationale has remained
relatively unchallenged. However, it is now clear that epigenetic changes (changes to the
DNA maintained by cell division other than alterations to the nucleotide sequence) play a
critical role during tumorigenesis (Feinberg and Tycko 2004). The genome of cancer
cells is characterized by localized hypermethylation in CpG islands, resulting in the
silencing of tumor suppressor gene expression (Baylin and Bestor 2002). In addition,
global genomic and CpG island hypomethylation are associated with both benign and
malignant tumors (Feinberg and Vogelstein 1983; Gama-Sosa, Slagel et al. 1983)).
Mechanistically these epigenetic changes are known to cause both oncogene activation
and chromosomal instability resulting in loss of heterozygosity (Feinberg and Vogelstein
1983) (Chen, Pettersson et al. 1998) (Gaudet, Hodgson et al. 2003).
Imprinted genes display a characteristic parent-of-origin specific DNA
methylation pattern that results in only a single allele being expressed (either the paternal
or maternal allele). DNA methylation that maintains the monoallelic expression of
imprinted genes is established during gametogenesis and is important for fetal growth
regulation and perinatal development (Bartolomei 2003) (Reik and Walter 2001).
Although imprinting persists in the adult, the requirements for proper imprinting in the
context of normal tissue homeostasis is not well understood.
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Loss of imprinting (LOI), either biallelic expression or complete silencing of
imprinted genes, has been implicated in the progression of several tumors (Ogawa, Eccles et
al. 1993; Rainier, Johnson et al. 1993). For instance, aberrant biallelic expression of the
Insulin-like growth factor-2 (IGF2) gene, a significant risk factor for human colorectal
carcinogenesis, is thought to promote tumorigenesis by inhibiting apoptosis (Cui, Cruz-
Correa et al. 2003). In addition PEG3, p57kiP 2 , and IGF2R all display LOI that leads to their
silencing in oligodendrogliomas, breast cancer, and hepatocellular carcinomas, respectively
(De Souza, Yamada et al. 1997; Kobatake, Yano et al. 2004; Trouillard, Aguirre-Cruz et al.
2004). Although there is evidence that LOI at the IGF2 locus promotes tumorigenesis in
Beckwith-Wiedemann syndrome (DeBaun, Niemitz et al. 2002), for the majority of human
tumors is has not been clear if LOI plays a causal role in cancer or is merely a consequence
of altered epigenetic regulation in already transformed cells. Furthermore, in all studies to
date, the effects of LOI on cancer progression have been restricted to either single loci or
have examined the consequences of a global imbalance of imprinting in parthenogenetic or
androgenetic cells (Hernandez, Kozlov et al. 2003). Thus, the effect of genome-wide LOI
on tumor formation has not been addressed.
Here, we use conditional alleles of Dnmtl, encoding a DNA methyl transferase, to
transiently remove all DNA methylation marks from the genome of embryonic stem (ES)
cells. Reactivation of Dnmtl expression resulted in a restoration of global DNA
methylation but failed to re-methylate imprinted genes. From these imprint-free (IF) ES
cells we derived murine embryonic fibroblasts (MEFs) and examined their growth
characteristics. The IF-MEFs displayed a number of characteristics of transformed cells
including increased growth rate, immortality, and resistance to growth inhibition by TGF3.
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When injected into SCID mice, the IF-MEFs formed tumors with long latency.
Overexpression of oncogenic V12 H-Ras in the IF-MEFs significantly shortened tumor
latency. Chimeric animals that were generated with the IF-ES cells developed widespread
tumors by 12 months of age, with the cancers being derived from the IF-ES cells. Our
findings suggest a causal link between LOI and cancer and demonstrate that imprinting
plays a critical tumor suppressor role in the adult.
2.4 Results.
2.4.1 Generation of IF and CTL-ES cells.
To investigate the role of LOI in the progression of cancer we took advantage of
previous observations in which mouse embryonic stem (ES) cells deficient in Dnmtl
(encoding an enzyme that maintains global DNA methylation) were found to lack global
DNA methylation, including the methylation associated with imprinting (Li, Beard et al.
1993). Although loss of Dnmtl through a conditional knockout allele has no effect on ES
cell viability, it is essential in differentiated cells (Jackson-Grusby, Beard et al. 2001).
Lethality and global DNA methylation have been rescued following re-expression of a
Dnmtl cDNA in the Dnmtl mutant ES cells(Tucker, Beard et al. 1996). However because
of the low Dnmtl level in the "rescued" cells, the genome was incompletely re-methylated
resulting in abnormalities such as genomic instability (Chen, Pettersson et al. 1998; Gaudet,
Hodgson et al. 2003). To circumvent these shortcomings, and to generate ES cells
expressing normal and properly regulated levels of Dnmtl, we devised an alternative
strategy in which Dnmtl was first conditionally inactivated and then reactivated by
sequential exposure of the cells to the cre and flp recombinases.
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Figure 2.1 Conditional alleles of Dnmt1
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Figure 2.1 Conditional alleles of Dnmt1
(A) Conditional inactivation of Dnmt1 2LoxP allele. Shows the recombination of Dnmt1
to 1LoxP when exposed to Cre-recombinase. (8) Conditional activation of Dnmt1 2Frt
allele. Shows the recombination of Dnmt1 allele to 1Frt and the removal of the stop cas-
sette when exposed to Flipe-recombinase.
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To do this we constructed an inactive Dnmtl allele (2-Frt) by inserting a STOP cassette
flanked by two Frt sites between the fourth and fifth exons of the Dnmtl gene. This mutant
allele is revertible and becomes re-activated following Flpe-mediated recombination (Fig
2.1B). Mice carrying the 2Frt allele were generated by injection of targeted ES cells into
mouse blastocysts, and the subsequent animals were bred to the Dnmtl 21ox(Jackson-
Grusby, Beard et al. 2001) and a ROSA26 Flp reporter allele (Possemato, Eggan et al. 2002)
(Fig 2.1A). ES cell lines containing the Dnmtl conditional 2-Lox and Dnmtl 2-Frt alleles,
and the Flp beta-geo reporter allele were derived from these animals (Fig 2.2A). When the
2-Lox/2-Frt ES cells were transfected with a Cre plasmid, deletion of exons 4 and 5 create
the null Dnmtl -Lox allele resulting in Dnmtl deficiency (Fig 2.2B). Consistent with this,
the -Lox/2-Frt cells displayed global genome demethylation as demonstrated by Southern
blot analysis of centromeric regions, LINE, and AP elements and (Fig 2.3A-C). The
demethylated cells were then transfected with a Flpe plasmid, causing the STOP cassette to
be excised (2-Frt -> 1-Frt), the Dnmtl allele to be reactivated, and genome methylation to be
restored (Fig 2.2A-B; these cells are herein referred to as 'IF-ES cells')(Buchholz, Angrand
et al. 1998). To serve as a control, we transfected 2-Lox/2-Frt ES cells with flpe first and
Cre second, a manipulation that maintains Dnmtl activity at each step and has no effect on
genomic methylation level and imprinting (referred to as 'CTL-ES cells)(Fig 2.2A).
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Figure 2.2 Generation of IF and CTL-ES cells
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Figure 2.2 Generation of IF and CTL-ES cells.
(A) Schematic representation of the steps used to create the IF-ES cells. Red and blue
indicate the Dnmt1 genotype. CTL-ES cells were generated by reverse exposure to the
recombinases. (8) Genomic southern blot analysis confirming the recombined Dnmt1
alleles. Lane 1, Wild-type Dnmt1; Lane 2, 2LoxP/2Frt Dnmt1; Lane3, 1LoxP/2Frt Dnmt1;
Lane 4, 1LoxP/1 Frt Dnmt1 .
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Figure 2.3 Genomic methylation state of IF and CTL cells
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Figure 2.3 Genomic methylation.
(A) The methylation status of the classic centromeric repeats from genomic DNA of con-
trol, ES and MEF cells. (B) The methylation status of lAP elements from genomic DNA
of control, ES and MEF cells. (C) The methylation status of LINE elements from genomic
DNA of control, ES and MEF cells.
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2.4.2 Expression and methylation of IF and CTL-MEFs.
To confirm that our strategy had successfully erased imprinting, we examined the
methylation status of selected imprinted genes in imprint-free ES cells and murine
embryonic fibroblasts (MEFs). To generate the MEFs, wild-type blastocysts were
injected with either IF- or CTL-ES cells and fibroblasts were isolated from E13.5
chimeras using G418-resistance to select for ES cell derived MEFs. As assessed by
Southern blot analysis, the restoration of normal global methylation was maintained in
the MEFs (Fig2.3 A-C). LOI at the Igf2r, Snrpn, Peg3, and Ig/2 loci was assessed by
methylation-sensitive Southern blotting and COBRA analysis(Xiong and Laird 1997).
While normal imprinted methylation of Ig/2r, Snrpn, and Peg3 was found in the CTL-ES
cells and CTL-MEFs, these genes lacked methylation in IF-ES cells and IF-MEFs,
consistent with LOI. In contrast, COBRA analysis revealed that the Differentially
Methylated Region (DMR) of the H19-Igf2 locus, a regulatory element that controls
expression of HI 9 and Igf2, was variably methylated in IF-ES cells and IF-MEFs
(Fig2.4). Although this result was contrary to expectation in our model, it was not
surprising, since the Ig/2-H19 DMR is highly susceptible to de novo methylation when
the methylation status of the genome has been altered (Tucker, Beard et al. 1996; Chen,
Pettersson et al. 1998; Biniszkiewicz, Gribnau et al. 2002; Baqir and Smith 2003)
whereas the methylation status of other imprinted regions is more stable. Loss of the
DNA methylation associated with imprinting is expected to either erase or result in
biallelic expression of imprinted genes depending on whether the methylation of the
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Figure 2.4 Characterization of methylation status of imprinted genes
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Figure 2.4. Characterization of Methylation status of IF- and CTL-MEFs.
Methylation status of imprinted genes in CTL and IF-MEFs was carried out by methyla-
tion sensitive Southern blot analysis for Igf2r and COBRA anaylsis for Igf2, Snrpn and
Peg3.
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Figure 2.5 Characterization of expression status of IF- and CTL-MEFs
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Figure 2.5. Characterization of Expression status of IF- and CTL-MEFs.
Confirmation of the expression of selected imprinted genes by northern blot and
RT-PCR analysis. Lanes 1 and 2 CTL-MEFs; Lanes 3, 4, 5 and 6 IF-MEFs.
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respective imprinting box or differentially methylated region (DMR) has a positive or
negative effect on transcription (Reik and Walter 2001).
To assess the effect of LOI on gene expression, we examined the gene expression
profiles of IF-MEFs and CTL-MEFs using microarrays. This analysis revealed a tight
clustering for most genes, indicating that there was very little difference in expression
patterns between the two populations (Pearson coefficient-r = 0.9919) (Fig 2.6A).
However, the expression of a small number of genes, mostly corresponding to known
imprinted genes, was altered (Fig 2.6B). The remaining genes were known or likely
downstream targets of imprinted genes (data not shown), although we cannot rule-out the
possibility that some represent non-imprint-related genes independently affected by our
demethylation/remethylation strategy. In agreement with our finding that the Igf2-H19
DMR was variably methylated, we found -2-fold higher level of Igf2 and no HI 9
expression in 2 of 4 IF-MEFs samples as compared to CTL-MEFs, and the other two IF-
MEFs were unchanged relative to the CTL-MEFs. To validate the microarray data,
expression of Megl/Grbl O, Igf2r, Igf2, HI 9, PegS, Pegl, Peg3 and p57 iP2 was examined
in the imprint-free and control MEFs by Northern blot analysis and RT-PCR, as
described in Experimental Procedures (Fig 2.5). This analysis confirmed that the IF-
MEFs were negative for Igf2r, Megl/Grb O, p5 7iP2 and variable for HJ9, but displayed
increased levels of Peg3, PegS and variable Ig/2 compared to CTL-MEFs. Our findings
suggest that the strategy of conditionally inactivating and then reactivating Dnmtl
successfully erased the methylation associated with imprinting, but not global genome
methylation, resulting in widespread alterations in the expression of imprinted genes.
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Figure 2.6 Micro Array Analysis of IF- and CTL-MEFs
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Figure 2.6 Micro array analysis of IF- and CTL-MEFs.
(A) Characterization of IF- and CTL-MEFs by microarray analysis. Full documentation
can be found at (http://www.ebi.ac.uk/arrayexpress; accession number E-MEXP-450).
(B) Selected imprinted genes that are up- or down-regulated in IF-MEFs by microarray
analysis.
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2.4.3 Altered growth properties of IF-MEFs.
Many imprinted genes such as Igf2 and GrblO/Megl have been implicated in
embryonic growth control (Reik and Walter 2001). We therefore examined whether IF-
MEFs displayed altered growth properties compared to CTL-MEFs. To analyze the cell
cycle in the MEFs, DNA content was measured by flow cytometry. The majority (-70%)
of the CTL-MEFs were in the G1 phase of the cell cycle with approximately 13% and
17% in the S- and G2/M-phases, respectively. In contrast, under the same culture
conditions, the IF-MEFs displayed a higher mitotic index with a lower proportion of cells
in the G1 - (46%) and S-phases (7%) and a pronounced increase in the proportion of cells
in G2/M (47%) (Fig 2.7). To determine if this altered cell cycle profile was indicative of
altered growth, we counted the total number of IF- and CTL-MEFs during an 8-day
interval and calculated the growth rate during the exponential phase of proliferation (2-4
days after plating, Fig 2.8A). The viability of the exponentially growing cells was
approximately 95% as assessed by Trypan blue dye exclusion. This analysis showed that
the IF-MEFs grew significantly faster than the control fibroblasts (Fig 2.8A), consistent
with a shortened cell cycle.
Microarray analysis revealed the down regulation in IF-MEFs of Ig/2r, Tspl and
p57 k ip2 (Fig 2.6B), three genes known to positively regulate transforming growth factory
(TGF3) activation and signaling. These gene expression changes coupled with the
increased growth rates in IF-MEFs suggested a potential inability of IF-MEFs to respond
to TGFP3, a pleiotropic cytokine that inhibits the growth of a diverse range of cell types
(Roberts and Wakefield 2003).
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Figure 2.7 Cell cycle characteristics of IF-MEFs
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Figure 2.7 Cell cycle characteristics of IF-MEFs.
Cell cycle analysis of IF and Ctl-MEFs by flow cytometry. A representative example of prop-
idium iodide stained MEFs is shown for both IF and Ctl. The three arrows indicate the peaks
that represent cells in G1J Sand G2/M phase of the cell cycle respectively. Below each graph
is the quantification of cells in each stage of the cell.
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Figure 2.8 Growth characteristics of IF-MEFs
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Figure 2.8 Growth Characteristics of IF-MEFs.
(A) Growth Rate of IF and CTL-MEFs. The graph shows the faster growth rate of IF-
MEFs compared to CTL-MEFs over a period of 8 days. (B) Lack of response of IF-
MEFs to the growth inhibitory cytokine TGF~.
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To investigate whether LOI altered the ability of MEFs to respond to TGF[3
growth-inhibition, we exposed IF- and CTL-MEFs to TGF[3 (0.1 ng/ml) 24 hours after
plating. Within 48 hours, the CTL-MEFs had undergone growth arrest (Fig 2.8B),
whereas the IF-MEFs continued to proliferate normally (Fig 2.8B). These results suggest
that IF-MEFs are no longer responsive to the growth-inhibitory effects of TGF3, a
property shared by malignant cells.
2.4.4 Immortalization and transformation of IF-MEFs.
Wild-type MEFs have a limited life-span in cell culture and eventually undergo
senescence. To determine the life-span of the IF-MEFs, we used the 3T3 protocol
(Todaro and Green 1963), which involves continuous passaging of the cells. By passage
8, CTL-MEFs had undergone senescence and appeared as large, flat non-dividing cells.
In contrast, IF-MEFs appeared to be spontaneously immortalized as they maintained a
constant proliferation rate and grew for at least 20 passages without showing any
indication of undergoing senescence (Fig 2.9). Among many of the changes associated
with cellular senescence in culture is the increased expression of cell cycle regulators
such as p16 nk4 a and pl9Arf that are thought to be critical in inducing permanent Go/GI
arrest (Kamijo, Zindy et al. 1997; Stein and Dulic 1998). Figure 2.10 shows that the level
of p 16 nk4a increased in later passages of IF-MEFs, comparable to that in CTL-MEFs. The
p21CiPl cell cycle inhibitor has been shown to have a similar function as p16LInk4a in
senescing human cells, although its role in mouse cells is less clear (Brown, Wei et al.
1997; Pantoja and Serrano 1999).
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Figure 2.9 IF-MEFs are immortal
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Figure 2.9 IF-MEFs are immortal. Immortalization was determined by accumulated
number of population doublings over continued passages.
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Figure 2.10 Analysis of Cell Cycle regulators
CTL IF1-------P2
p1611
p21
p19.
p53
IF2
P9 P21
Figure 2.10 Western blotting analysis of cell cycle regulators in CTL-MEFS and IF-
MEFS at increasing passages.
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Ink4aLike p16 nk4 a, the levels of p21CiPl remained constant or increased in the late
passages of IF-MEFs (Fig 2.10). In contrast, the level of pl9" f did not increase in later
passages of IF MEFs and were significantly less than in CTL-MEFs (Fig 2.10). Because
p19A f is known to bind to and sequester MDM2 and to inhibit the MDM2-dependent
degradation of p53 (Sherr and Weber 2000), we examined the level of p53 in early- and
late- passages IF-MEFs. In early passages, p53 was present but, as expected from the
decreased level of pl9m f , p53 expression decreased significantly at later passages (Fig
2.10).
Immortalization is an essential prerequisite for malignant transformation in
mammals (Hahn and Weinberg 2002). Therefore we tested the transformation potential
of IF-MEFs using the classic foci formation assay. This assay involves the maintenance
of confluent cells over a 3-week period without passaging. In the rare incidence that a
cell becomes transformed it escapes quiescence and forms a dense outgrowth known as a
focus. When CTL-MEFs were grown under these conditions, 1.3 + 0.6 foci were found
per plate (Fig 2.11 A-Ctl & B-Ctl). In contrast, IF-MEFs formed approximately 35 ± 2.4
foci (Fig 2.11 A-IF & B-IF), consistent with LOI predisposing the IF-MEFs to
spontaneous transformation.
Ig/2 is an imprinted gene that often exhibits LOI and aberrant biallelic expression
in human tumors (Cui, Cruz-Correa et al. 2003). To determine if biallelic expression of
Ig/2 was solely responsible for the immortality and the increased rate of spontaneous
transformation of the IF-MEFs, we overexpressed Igf2 in CTL-MEFs following
retrovirus mediated transduction.
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Figure 2.11 Transformation of IF-MEFs
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Figure 2.11 Transformation of IF-MEFs.
(A) Spontaneous transformation of IF-MEFs measured by the fociassay. IF-MEFs 34.9
:t 2.4; CTL-MEFs 1.3 :t 0.6; CTL-lgf2 6.1 :t 1.5; CTL-Vector 1.0 :t 0.93. (8) Representa-
tiveplate demonstrating the spontaneous transformation present in the IF-MEF foci
assay.
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While Igf2 overexpression in CTL-MEFs led to an increased growth rate, it only
led to immortalization after extensive passaging as previously reported (data not shown
and (Hernandez, Kozlov et al. 2003). In the foci formation assay, Igf2-infected CTL-
MEFs (at low passage number) formed approximately six fold more foci than vector-only
infected CTL-MEFs (6.1 1.5 and 1 + 0.9 foci, respectively) but failed to induce the
level of spontaneous transformation observed with IF-MEFs. These data combined with
the northern and micro-array analysis suggest that the variable expression levels of Ig/2
contribute to the ability of the cells to spontaneously transform. However, LOI of
additional genes is needed to achieve the full extent of immortalization and
transformation seen in IF-MEFs.
Forced overexpression of the oncogenes SV40 Large T antigen (LgT) and a
constitutively active growth signal, such as that provided by V12 H-Ras, in wild-type
MEFs is sufficient to cause cellular transformation. However, MEFs V12 H-Ras alone
will not become transformed, but instead are either immortalized by LgT or are induced
to undergo senescence (Hahn and Weinberg 2002). Given that the IF-MEFs displayed a
greater potential for spontaneous transformation, we asked whether the effect of LOI
could replace the function of either LgT or active H-Ras in this process. IF- and CTL-
MEFs were infected with a LgT retroviral vector or an empty vector and drug selection
was used to select for transduced cells. The cells were plated at low density and focus
formation was assessed after a 14-day culture period. As expected, LgT-infected CTL-
MEFs formed a greater number of foci as compared to the vector-only CTL-MEFs,
similar to previous reports.
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Figure 2.12 Morphology of IFHRas-MEFs
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Figure 2.12 IF-MEFs infected with V12-HRas (IF-Ras) show altered morphology when
compared to IF-MEFs (IF) alone.
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Figure 2.13 Growth rate and Foci formation of IFRas-MEFs
3000
A
2500,.....
C'I)
0
PI
)( 2000~
.!
Gi
U 1500...
0
I.
CD
.c 1000E
~Z
500
o
1 2 3 4
Days
5 6 7 8
B IFHRas IF
Figure 2.13
(A). IF-HRas-MEFs grow at a significantlyfaster rate than IF-MEFs. (8) Representative
plate demonstrating spontaneous transformation in the low density foci assay compar-
ing IF and IF-HRas.
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Although the vector-only infected IF-MEFs formed more foci than the respective
CTL-MEFs, no further increase in foci numbers were observed in the LgT-infected IF-
MEFs (data not shown). Thus, LOI and LgT expression do not cooperate in cellular
transformation.
To ask whether LOI can replace the function of LgT and cooperate with activated
H-ras, we examined the effect of V12 H-Ras expression on IF-MEFs transformation
frequency. CTL- and IF-MEFs were infected with either a V12 H-Ras or an empty
retrovirus vector. Expression of V12 H-Ras in CTL-MEFs induced an immediate
inhibition of cell growth and quiescence after passaging (data not shown), consistent with
previous studies (Serrano, Lin et al. 1997). In contrast, IF-MEFs infected with V12 H-
Ras lost contact inhibition, exhibited a significant change in morphology and continued
to proliferate at a significantly higher rate than the vector-only control IF-MEFs (Fig
2.12; 2.13). In the focus formation assay, the V12 H-Ras-infected IF-MEFs displayed a
massive increase in focus formation compared to vector-only infected IF-MEFs (Fig
2.13). These results indicate that LOI cooperates with V12 H-Ras to fully transform
MEFs.
2.4.5 Tumor formation
The tumorigenic potential of cells was tested in vivo by sub-cutaneous injection
into Severe Combined Immuno-deficient (SCID) mice, which lack mature lymphocytes.
In this assay, fully transformed cells will form tumors beneath the skin at the site of
injection.
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Table 2.1 Incidence of MEF derived fibrosarcomas in SCID mice.
Table 2.1 Incidence of MEF-derived fibrosarcomas in SCID mice.
2 x 106 MEFs were injected into three independent sites and growth of tumors was
assessed after the defined time point.
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MEFs SCID Mouse Fibrosarcomas
8-12 Days 4-5 Months
CTL 0/6 0/6
CTL+LgT 0/6 0/6
IF 0/6 2/6
IF+LgT 0/6 2/6
IF+Ras 7/7 N/A
Using this assay, we compared the tumorigenic potential of CTL- and IF-MEFs
infected with either LgT or empty vector and IF-MEFs infected with V12 H-Ras. No
tumors were found in SCID mice after 4-5 months following injection with CTL-MEFs
(0/7) or LgT-infected CTL-MEFs (0/7). Tumors were observed in SCID mice injected
with IF-MEFs (2/6), or LgT-infected IF-MEFs (2/6) after 5 months. In contrast, all SCID
mice injected with V12 H-Ras-infected IF-MEFs (7/7) formed large fibrosarcomas within
14 days post-injection (Table 2.1). These findings are consistent with cooperation
between LOI and oncogenic Ras to induce a fully transformed phenotype in MEFs. It
should be noted that, due to the senescence that occurred in V12 H-Ras infected CTL-
MEFs there were insufficient cells to perform the tumor formation assay in SCID mice.
To further examine the role LOI plays in oncogenesis in vivo, we created chimeric
mice using IF- and CTL-ES cell lines (using two independently-derived ES cell lines for
each condition). The level of chimerism contributed by the IF-ES cells ranged from 5-
20% in the adults, whereas CTL-ES cells contributed up to 100%, as judged by coat
color. Chimeras were sacrificed at 9, 12 and 18 months of age and their tissues were
examined histologically for abnormalities. Strikingly, about half of the IF-chimeras at 9
months of age (n= 3/5) and all of the chimeras at 12 and 18 months of age showed the
presence of hepatocellular tumors and intestinal adenomas (Table 2.2; Fig 2.14 A-E).
The hepatocellular carcinomas, and in some cases adenomas, averaged approximately 5 x
6 mm in size (n=6; data not shown) by 18 months of age.
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Table 2.2 The incidence of tumors in IF-chimeras.
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IF Tumor Incidence 9 Months 12 Months 18 Months
Hepatocellular Carcinomas 4/5 7/7 4/4
Intestinal Adenomas/Carcinomas 3/5 3/3 4/4
Testicular Seminoma 0/5 0/7 1/4
Lymphoma 0/5 1/7 0/4
Leukemia 0/5 1/7 0/4
Other cancers were also observed, for instance in one IF-chimera the normal
architecture of the testis was disrupted by a proliferation of homogenous cells consistent
with testicular seminoma (Fig 2.14E). Another IF-chimera displayed splenomegaly and
histological analysis of the bone marrow revealed a phenotype consistent with a leukemia
(Fig 2.14D). In a 12-month old IF-chimera, a large tumor with histology consistent with
lymphoma was isolated (Fig 2.14C). In contrast to these results, control chimeras
appeared healthy at all time points, and when sacrificed at 24 months of age displayed no
tumors (n=6/6; up to 100% chimerism assessed by coat color contribution).
To confirm that the cancers in the IF-chimeras were derived from the IF-ES cells,
genomic DNA from tumors was analyzed by PCR for the presence of the neo fragment of
the beta-geo gene contained in the IF-ES cells but not in the BDF1 host tissue. The neo
gene was amplified from all of the tumors examined, consistent with an IF-ES cell origin
for these neoplasms (Fig 2.14F). Taken together, tumorigenic potential of both IF-ES
chimeras and IF-MEFs provides strong evidence that LOI promotes transformation both
in vitro and in vivo.
In humans, the imprinted genes p5 7 kip2, Ig/2r, and Ig/2 have been implicated in the
tumorigenesis of multiple cancers (Mills, Falls et al. 1998; Feinberg and Tycko 2004).
We therefore examined the expression of these genes in tumors from the IF-chimeras.
Similar to our results in IF-ES cells and IF-MEFs, transcripts for p 57 kiP2 and Ig/2r were
absent in the tumors (Fig 2.15A Igf2r, p 5 7 kip2 Lanesl-4), whereas variable levels of Ig/2
expression was found (Fig 2.15A Igf2 Lanesl 1-4).
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Figure 2.14 Histological analysis of IF tumors
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Figure 2.14 Histological analysis of IF tumors.
Histological analysis of tumor formation in IF chimeras stained with H&E. (A) Sections of an
IF hepatecellular carcinoma/adenoma. (B) Intestinal adenoma/carcinoma, (C) Lymphoma,
(D) Chronic myeloid-like leukemia, (E) Testicular seminoma. (F) Genomic peR to detect the
presence of the IF neomycin marker gene. Lane 1, BDFI wildtype host blastocyst; Lane 2,
hepatocellular tumor 1; Lane 3, hepatocellular tumor 2; Lane 4, hepatocellular tumor 3; Lane
5, testicular seminoma; Lane 6, intestinal adenoma; Lane 7, Chronic myeloid-like leukemia;
Lane 8, Lymphoma.
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Figure 2.15 Expression analysis of IF tumors
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Figure 2.15 Expression analysis of IF tumors.
(A) RT-PCR expression analysis of selected imprinted genes in IF tumors. Lane 1, hepatocel-
lular carcinoma; Lane 2, testicular seminoma; Lane 3, chronic meyloid-like leukemia; Lane 4,
lymphoma; Lane 5, wild-type liver; Lane 6, wild-type testis; Lane 7, wild-type bone marrow;
Lane 8, wild-type spleen. (B) Methylation status of selected imprinted genes in IF tumors by
COBRA (/g'2) and methylation sensitive southern blotting (/g'2r) analysis. Lane 1, hepatocel-
lular carcinoma; Lane 2, intestinal adenoma; Lane 3, testicular seminoma; Lane 4, chronic
myeloid-like leukemia; Lane 5, lymphoma; Lane 6, wild-type Liver; Lane 7, wild-type intestine;
Lane 8, wild-type testes; Lane 9, wild-type spleen; Lane 10, wild-type bone marrow.
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In agreement with our findings in IF-MEFs (Fig 2.4), the tumors displayed
methylation of the H19-Igf2 locus (Fig 2.15 B Igf2 Lanes 1-5). These results indicate
that the tumors observed in the chimeras display a loss of transcripts for the putative
tumor suppressors p5 7 kiP2 and IgJ2r and variable expression levels of the IgJ2 oncogene,
similar to that observed in the parental IF-ES cells and IF-MEFs.
2.4.6 No tumors after germline transmission.
Imprinted genomic methylation is established during gametogenesis (Tucker,
Beard et al. 1996), predicting that the breeding of adult IF-chimeras should "re-set" the
methylation state and result in progeny with normal imprinting. To test whether
restoration of normal imprinting would revert the tumorigenic phenotype, consistent with
an epigenetic basis for these cancers, IF-chimeric mice from the two independently
derived IF-ES and CTL-ES cells were crossed to C57B6 mice. Progeny inheriting the ES
cell derived genome, as determined by coat color, were aged and examined for tumors at
autopsy. Careful histological analyses failed to detect tumors at 18 or 24 months of age
(n=0/8) with the exception of a single lung adenoma detected at 24 months of age (n=l/5)
in a CTL mouse (Table 2.3). Due to the age of this animal this is most likely a
spontaneous tumor and not caused by genetic manipulation of the parental ES cell line.
The reversibility of the tumorigenic potential of IF-cells following germline passage
supports the epigenetic basis of these cancers, and argues against the tumor formation in
the IF chimeras was due to an oncogenic mutation incurred during the culturing of the ES
cells.
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Table 2.3 Tumor incidence after germline transmission.
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Tumor Incidence after Germline Transmission 18 Months 24 Months
Control 0/3 1/2
IF 0/4 0/4
2.5 Discussion.
It has been known for some time that altered DNA methylation is associated with
both benign and malignant tumor states. Considerable attention has focused on the effect
of global hypo- or hypermethylation of DNA in tumors, whereas considerably less is
known about the importance of imprinting during cancer progression. The goals of this
study were to engineer mice with global LOI and then examine the involvement of
imprinting in tumorigenesis. By sequentially eliminating and then reestablishing Dnmtl
expression in ES cells we generated cells which possessed normal global DNA
methylation but lacked the methylation associated with imprinting (with the exception of
the Igf2/H19 locus). Gene expression analyses confirmed the success of our approach,
with imprinted genes being either silenced or upregulated -2-fold in IF-MEFs compared
with control cells. An analysis of the growth and cell cycle characteristics of IF-MEFs
revealed that LOI conferred a number of characteristics possessed by transformed cells,
including a higher growth rate, a shortened cell cycle time, cellular immortality,
resistance to TGFfi3, and foci formation on a confluent monolayer. Consistent with this,
IF-MEFs formed tumors in SCID mice and more significantly, adult chimeric mice
derived from IF-ES cells developed tumors in multiple tissues. These data demonstrate
that in addition to regulating normal embryonic growth, imprinting plays a much wider
role in tissue homeostasis by providing an essential tumor suppressor function in the
adult.
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Previous studies have implicated altered imprinting at the Igf2/H19 locus with
cancer formation. In the case of Wilms tumors in the rare Beckwith-Wiedmann
syndrome (BWS), specific loss of normal imprinting on the maternal H19 allele leads to
biallelic expression of IGF2 expression and is thought increase the number of pre-
malignant nephrogenic precursors (Okamoto, Morison et al. 1997; Ravenel, Broman et al.
2001). In recent mouse studies, it was shown that the number of intestinal tumors that
form in Apc+/min mutant mice was increased when Igf2 was biallelically expressed
(Sakatani, Kaneda et al. 2005). These studies suggested that a loss of normal imprinting
at the Igf2/H19 locus contributes to Wilms tumors and APC-induced intestinal tumors.
However, it is unlikely that deregulated Igf2 expression was solely responsible for the
transformed phenotype we observed caused by global LOI. In our study, the Ig12/H19
DMR was variably de novo methylated following re-expression of Dnmtl. This was an
expected finding because Ig2/H19 DMR, unlike other imprinted loci, has been shown to
be highly susceptible to de novo methylation during cancer progression (Feinberg and
Tycko 2004), following reactivation of high levels of Dnmtl in Dnmt-l -' mutant cells
(Biniszkiewicz, Gribnau et al. 2002), and during in vitro cultivation of preimplantation
embryos (Latham, Doherty et al. 1994; Mann, Lee et al. 2004). As a result of stochastic
methylation at the Ig/2/H19 DMR in both the IF-MEFs and tumors, the expression of Igf2
(and H19) was variable (ranging from normal to approximately biallelic levels in the IF-
MEFs). Therefore it is unlikely that the enhanced tumorigenic potential of cells with LOI
can be solely attributed to altered expression of Igf2. Consistent with this, re-activating
monoallelic expression of Igf2r, which functions in the inactivation of Igf2, only slightly
reduces the level of spontaneous transformation of IF-MEFs (T.M.H and R.J,
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unpublished results). Similarly, overexpression of Igf2 in CTL-MEFs was not sufficient
to induce the high rate of spontaneous transformation that was observed with IF-MEFs at
low passage number (4-6), although it led to an increased growth rate. We note that at
higher passage numbers (>15), MEFs forced to overexpress Igf2 undergo spontaneous
transformation, which is likely the result of secondary mutations that accrue during
extensive passaging (Hernandez, Kozlov et al. 2003). Based on these observations, we
conclude that imprinted loci other than Igf2/H19 and IgJ2r are primarily responsible for
the altered growth characteristics and transformed phenotype of cells with LOI.
Immortalization is an essential prerequisite for the formation of a tumor cell, as
the introduction of an oncogene into a mammalian cell that is not immortalized will
induce senescence or apoptosis due to the activation of anti-neoplastic defense
mechanisms (Hahn and Weinberg 2002). It is for this reason that pairs of cooperating
oncogenic mutations are needed to transform mouse cells, as the second oncogene is
usually required to neutralize the protective pathways triggered by the first oncogene.
For instance, overexpression of oncogenic V12 H-Ras alone in MEFs leads to an
upregulation of p19Arf and premature growth arrest. Senescence can be avoided in these
cells by inhibiting the p19Af-p53 pathway (Serrano, Lin et al. 1997). Similarly, our data
suggest that LOI confers immortality to MEFs by inactivating the p1 9 Af-p 5 3 pathway.
Western blot analysis revealed a significant decrease in the levels of pl9 a ' f and p53 in IF-
MEFs. Consistent with this, overexpression of LgT in IF-MEFs, which binds to and
inactivates p53, did not enhance tumor formation in the SCID assay. In contrast,
overexpression of V12 H-Ras in IF-MEFs failed to induce growth arrest and instead
cooperated with LOI to induce tumors with short latency in SCID mice. Given the role
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of pI9Arf in protecting p53 from MDM2-dependent degradation, it is possible that the
reduction in p53 in IF-MEFs results indirectly from a loss of p 9 Arf. At present, the
imprinted gene/s responsible for the reduction in p19d f and p53 protein levels are
unknown and further study is required for their identification.
Deregulated TGFI3 signaling is a common feature of malignant cells. In the early
stages of tumorigenesis, TGFfP inhibits cell growth by inducing apoptosis and arresting
the cell cycle. As cells progress toward a fully malignant tumor phenotype they become
resistant to the growth inhibiting effects of TGF[3, while other TGF[3 responses remain
fuilly operative (Roberts and Wakefield 2003). At present, the molecular mechanisms by
which cancer cells acquire this selective resistance are unclear. Our results indicate that
LOI provides one mechanism by which cells can become resistant to the growth
inhibitory effects of TGF3. At least three imprinted genes have been implicated in TGF[3
signaling (Tsibris, Segars et al. 2002). TSP-1 and IGF2R act as non-signaling receptors
for TGF3 and facilitate the cleavage and activation of the latent (preproprotein) ligand
(Godar, Horejsi et al. 1999; Murphy-Ullrich and Poczatek 2000). LOI-induced loss of
Tsp-1 and Ig/2r expression, resulting in a failure to process latent TGF3, is unlikely to be
responsible for the lack of TGFf3 responsiveness as IF-MEFs also failed to respond to
active, cleaved ligand. pS7 kP2 is a more likely candidate, as this gene encodes a putative
tumor suppressor that belongs to the Cip/Kip family of cyclin-dependent kinase (CDK)
inhibitors and acts as a negative regulator of the cell cycle(Deshpande, Sicinski et al.
2005). In human hematopoietic cells, p57 i p2 is upregulated by TGF3 and is essential for
mediating its cytostatic effects on blood cells (Scandura, Boccuni et al. 2004). Whether
p57kip2 plays a similar role in MEFs has yet to be determined. A third possibility comes
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from the recent discovery that p53 plays a key role in TGFP-induced growth arrest
(Cordenonsi, Dupont et al. 2003; Takebayashi-Suzuki, Funami et al. 2003). p53'- MEFs
show a defective cytostatic response to TGFfi3 and an inability to upregulate the CDK
inhibitor p21licP (Cordenonsi, Dupont et al. 2003). Furthermore, p53 interacts with
Smad2 and Smad3, downstream mediators of TGFI3 signaling, where it appears to
function as part of a transcriptional complex (Liberati, Datto et al. 1999; Labbe,
Letamendia et al. 2000; Cordenonsi, Dupont et al. 2003; Seoane, Le et al. 2004). It is
tempting to speculate that the mechanism by which LOI inhibits the pl9Arf-p53 pathway
to immortalize MEFs is related to its ability to confer resistance to TGF-induced growth
arrest. Further study is required to unravel the importance of p53 in LOI-induced
tumorigenesis.
Consistent with LOI rendering MEFs highly susceptible to transformation, all
chimeric mice derived from IF-ES cells developed tumors in multiple tissues. This
suggests that global LOI has a causal role in promoting cancer. The most common
cancers were hepatocellularcarcinomas and intestinal adenomas. It is unclear why this
particular spectrum of cancer was observed in the IF-chimera mice. It is possible,
however, that tumorigenesis may be due to the dysregulation of imprinted tumor
suppressor genes and oncogenes specific to each organ. The long latency of tumor
development indicates that LOI sensitizes cells to cancer and that additional somatic
events are required for tumor development. Offspring derived from chimeric mice that
had inherited the ES cell derived IF genome were cancer free. This indicates that the
aberrant state of genomic imprinting in the IF-ES cells is fully reversible after passage
through the germ line, consistent with the fact that the methylation associated with
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imprinting can only be established in germ cells. If the tumorigenic phenotype in the LOI
model was caused by a random mutational event during ES culture, then tumors would be
expected to also arise in the F1 progeny. Although it is possible that an oncogene or
tumor suppressor gene may have been improperly methylated (and thereby became
abnormally expressed) during the generation of the IF-ES cells, we would have expected
to detect such an abnormality from the microarray analysis. Furthermore, the likelihood
of such an event occurring in two independently derived IF-ES cell lines but not the
CTL-ES lines is small.
In summary, the ability of a cell to become immortal is a prerequisite for
transformation and ultimately tumor formation. By manipulating the maintenance
methylase Dnmtl we were able to generate ES cells that lack the methylation marks
required for maintaining imprinting, leading to global LOI. Our study provides strong
evidence that LOI predisposes cells to cancer. The data support a model in which LOI at
key loci encoding tumor suppressors and oncogenes provides the first step towards tumor
formation by conferring cellular immortality. Furthermore, our results are consistent
with subsequent genetic alterations, such as constitutive activation of a mitogenic signal,
providing the next step necessary for a fully transformed phenotype both in vitro and in
vivo.
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2.6 Experimental Procedures
2.6.1 2-Frt flanked Dnmtl inactive allele.
We constructed an inactive Dnmtl allele (2-Frt) by inserting a STOP cassette flanked by
two Frt sites between the fourth and fifth coding exons in the Dnmtl gene. This allele
becomes re-activated following Flp-mediated recombination (Fig 1).
2.6.2 Generation of imprint free and control ES cells.
All experiments on live vertebrates were preformed in accordance with relevant
institutional and national guidelines and regulations. Massachusetts Institute of
Technology's committee on animal care has approved the experiments and has confirmed
that all experiments conform to the relevant regulatory standards. The most recent
review and approval received on November 4 h 2004.
Mice heterozygous for the inactive 2Frt Dnmtl allele were crossed to mice
homozygous for the conditional 2LoxP Dnmtl allele(Jackson-Grusby, Beard et al. 2001)
and the ROSA26-13-geo Flp reporter allele (Possemato, Eggan et al. 2002). Fertilized
embryos were dissected at E0.5, cultured until the blastocyst stage, and explanted for ES
cell line derivation as described (Hochedlinger and Jaenisch 2002). ES cells were
cultured as previously described (Li, Bestor et al. 1992). Two independently derived ES
cell lines tested positive for both the 2Frt and the 2LoxP Dnmtl alleles. These cells were
exposed to Cre-recombinase through lipofectamine mediated, transient transfection. After
short-term puromycin selection positive, clones were picked, expanded and their genomic
DNA extracted. Clones were analyzed for Cre mediated recombination of the Dnmtl
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(2LoxP to LoxP) allele by southern blotting. Positive clones were expanded and the
process repeated with exposure to Flpe-recombinase to excise the stop cassette and
reactivate Dnmtl expression. The resultant doubly recombined Dnmtl ES cells were
termed IF (Figl). Control ES cells (CTL) were generated by exposure to the same
recombinases but in the reverse order (Fig 1). Genomic DNA was extracted from ES
cells at each stage of recombination for each Dnmtl genotype 2Loxp/2Frt, LoxP/2Frt,
2LoxP/lFrt and LoxP/lFrt. Southern blotting analysis was carried out after methylation
sensitive digestion with HpaII. Repetitive regions and elements known to be methylated
were probed, these included classic centromic satellite repeats, AP and LINE element
(Biniszkiewicz, Gribnau et al. 2002)(Fig 3).
2.6.3 Derivation of primary embryonic fibroblast cell lines from IF- and CTL-ES
cells.
MEFS were derived from day 13.5 embryos obtained by injecting IF and CTL-ES
cells into wild-type BDF1 blastocysts and implanted into foster mothers. IF and CTL
MEFs derived from chimeric embryos were selected for two passages with the
appropriate antibiotics. MEFs were frozen at passage 2 or 3 and with the exception of
long-term culture were used for all experiments before passage 6. Only pure populations
were used as assayed by genomic southern or PCR. MEFs and 293T ecotrophic
packaging cell line were grown in DMEM supplemented with 10% FBC, 5mM
Glutamine and penicillin/streptomycin. All the cells used tested negative for
mycoplasma.
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2.6.4 Characterization of the methylation and expression status of IF- and CTL-
MEFs.
Genomic DNA was extracted from MEFs isolated from different chimeric fetuses
and methylation analysis of selected imprinted genes was preformed by two different
methods. Methylation sensitive enzymatic digestion followed by southern blotting was
used to probe for Igf2r methylation (Biniszkiewicz, Gribnau et al. 2002). COBRA
analysis was used to analyze the methylation status of Igf2 Snrpn and Peg3 (Lucifero,
Mertineit et al. 2002). Expression analysis of selected imprinted genes was carried out by
two different methods using total RNA extracted from different clones of CTL- and IF-
MEFs. Ig/2r, H19, Igf2, PegS and GrblO expression was analyzed by Northern blotting
using cDNA probes to the open reading frame of these genes. p5 7kiP2, Pegl, and Peg3
expression was analyzed by RT-PCR using the following primers. p5 7kip2 forward
ctgacctcagacccaattcc and reverse gttctcctgcgcagttctct. Peg] forward gctggggaagtagctcagt
and reverse tttcttcttagcaagggcca. Peg3 reverse cttctggaagccgacattatc and forward
cctgatcaatgggttccttg. ,6-Actin forward ggtcagaaggactcctatgtgg and reverse
tccctctcagctgtggtggt
2.6.5 Microarray analysis of IF- and CTL-MEFs.
Arrays were manufactured from the Mouse Genome Oligo Set V3 (Operon),
containing 31,769 oligo probes. Oligos were printed onto CodeLink Activated Slides
(Amersham) using an Omnigrid 100 printer (Genemachines). Printing and post
processing of arrays was carried out according to the manufacturers instructions, using a
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modified print buffer containing 250mM phosphate buffer (pH 8.5), with 0.00025% N-
Lauroylsarcosine.
For expression profiling, 5tg of total RNA from independent IF-MEF (n=6) and
CTL-MEF (n=2) populations were reverse transcribed using a T7-oligo-d(T)-primer
(TCTAGTCGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGT 2 lN).
Second strand cDNA was synthesized as previously described (Gubler and Hoffman
1983). Double stranded cDNAs were purified and in vitro transcribed with the
Microarray RNA Target Synthesis Kit T7 (Roche). Unlabelled cRNAs were purified and
1 [tg cRNA per channel was labelled with 1 [tl Cy5 or Cy3 using the Micromax ASAP
RNA labelling kit (Perkin Elmer). Arrays were hybridized, washed and dried according
to the Agilent 60-mer oligo microarray processing protocol.
Arrays were scanned with a GenePix400B Scanner (Axon Instruments) and
expression data was extracted by Genepix Pro 6 Software (Axon). Data normalization
within and between arrays was performed with the Limma software package of the
Bioconductor project (Smyth 1983).
2.6.6 Retroviral infection assay
MEFs were infected with a high titer of retrovirus stocks produced by transient
transfection of 293T cells with an ecotrophic packaging virus. pBabe-blast or pWZL-
blast cells containing the retroviral infection were selected out with Blactocydin. The
pBabe-blast and pWZL-blast vectors containing constitutively active V12H-Ras or Large
T antigen cDNA, respectively were both gifts of R. Weinberg (The Whitehead Institute).
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2.6.7 Immunoblotting
Whole-cell extracts of exponentially growing cells were prepared in lysis buffer
(65 mM Tris pH7, 1% NP40, 2 mM EDTA, 100 mM NaC1) containing the Complete
cocktail of proteases inhibitors (Roche), and protein concentrations were determined with
the BioRad D/C protein assay reagent. Immunoblot analysis of p53 (Oncogene, AB-3, 1
: 500 ), p16 ln k4a (Santa Cruz, M-156, 1: 1000), p21CiP (Santa Cruz, F-5, 1: 1000) p19 Arf
(Novus Biological, AB80-100, 1: 500) was performed with 60 g of proteins run on
12.5% acrylamide gels transferred to Immobilon-P (Millipore). Secondary antibodies
coupled to HRP were purchased from Jackson ImmunoResearch Laboratories and used at
1: 10000. Detection was performed by chemiluminescence.
2.6.8 Growth Curves, immortalization and transformation assays
All experiments were repeated at least 3 times using cells from a minimum of 5
different fetuses for each genotype. For growth curves 3 x 104 cells were plated into 12
well dishes and fed every 2ndday. Serial 3T3 cultivation was conducted as described. To
test the ability of the cells to form multiple layers (foci formation assay), lx105 cells were
plated in triplicate for each of the different genotypes and grown for 28 days the medium
was changed every second day. Plates were then fixed in ice-cold methanol and stained
with crestal violet. Low density foci assays were conducted by plating 1.3 x 103MEFs as
described (Sage, Mulligan et al. 2000). To test tumorigenicity, exponentially growing
cells were resuspended in PBS and 1 x 106 cells were injected subcutaneously into SCID
mice. Tumor development was monitored for up to 6 months. IF and CTL-MEFs
infected with pBabe V12HRas-blastoiciden, pBabe-blastociden, pWZL Large T antigen-
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blastociden and pWZLGFP-blastociden were selected for three days in 2ug/ml blasticiden
and then replated to be expanded for foci formation assays and injection into SCID mice.
2.6.9 TGFIP and the cell cycle.
Cells were plated at 3 x 10 4 in 12 well plates from 6 different embryos for each
genotype in triplicate and 24 hours later exposed to TGFI3 at a concentration of 0. lnM.
Cells were then counted each day for 5 days. Cells were prepared for cell cycle analysis
as described (Brugarolas, Bronson et al. 1998). Samples were processed using FACScan
apparatus (Becton Dickinson) and the data were analyzed using ModFit LT software
(Becton Dickinson).
2.6.10 Generation of imprint free chimeric mice and histological analysis
IF- and CTL-ES cells were injected into wild-type BDF1 blastocysts. Chimeric
animals were born and allowed to age for time points, 9, 12, 18 months. Tumors were
removed at necropsy from chimera animals and fixed in formalin for sectioning and later
stained with H & E
2.6.11 PCR, RT-PCR and methylation tumor analysis
Genomic DNA from all tumors was extracted and tested for the presence of the
neomycin gene using the following primers, forward AAG CCG GTC TTG TCG ATC
AG and reverse GAT ATT CGG CAA GCA GGC AT. The methylation status of
genomic DNA associated with Ig/2 and IgJ2r was assessed by COBRA and methylation
sensitive digestion and southern blotting respectively (Biniszkiewicz, Gribnau et al. 2002;
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Lucifero, Mertineit et al. 2002). RNA was extracted from tumors using the Qiagen
RNasy Kit and reverse transcriptase PCR was preformed using the following primer pairs
for these genes. Igf2 forward tgcttctcatctctttggcc and reverse ggcacagtatgtctccagga. Igf2r
forward gtgtggtatttttatgtatagttagg and reverse aaatatcctaaaaatacaaactacac. p 5 7 kip2 forward
ctgacctcagacccaattcc and reverse gttctcctgcgcagttctct. i - Actin forward
ggtcagaaggactcctatgtgg and reverse tccctctcagctgtggtggt.
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3.1 Abstract
Imprinting, a mammalian adaptation whereby subsets of genes are differentially
expressed depending on their parental origin, is thought to be maintained by DNA
methylation. The 'parental conflict' hypothesis has been proposed to explain imprinting
and is based on a conflict between the mother and father over the allocation of maternal
resources to the embryonic offspring. To examine the effect of global loss-of-imprinting
(LOI) on development, we generated imprint-free embryonic stem (IF-ES) cells by
conditionally inactivating and then reactivating the DNA methyltransferase, Dnmtl. In
addition, we erased the imprint methylation marks in androgenetic ES cells (IFAT-ES)
and examined the developmental potential of IF-ES and IFAT-ES cells by tetraploid
complementation, relative to control ES cells. IF-ES and IFAT-ES cells were unable to
support development to full-term gestation and the resulting embryos ceased developing
at E1 1.5 and E9.5-10.5, respectively. Interestingly, IFAT-embryos developed further
than control AT-embryos, which failed to develop beyond at E8.5. Using chimera
studies, we showed that both IF- and IFAT-ES cells retained pluripotency in contrast to
AT-ES cells. The chimera studies also demonstrated that LOI induces an overgrowth
phenotype in IF-embryos, which likely contributes to their lethality. Restoration of
normal monoallelic expression of the imprinted gene Igf2r, a negative regulator of
embryonic growth, extended development of IF-embryos to day E12.5, but was unable to
rescue the overgrowth phenotype or lethality. Furthermore, our results indicate that
androgenetic ES cells that are devoid of imprint methyl marks are not equivalent to IF-
ES, suggesting that mechanisms other than DNA methylation may maintain imprinting.
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3.3 Introduction
Nuclear transfer experiments have demonstrated that the maternal and paternal
genomes are nonequivalent, and both are required for normal development of the mouse
embryo (Barton, Surani et al. 1984; McGrath and Solter 1984; Surani, Barton et al.
1984). The differences between the paternal and maternal genome are inherited from the
gametes in which parental imprinting of the genome is established. Genomic imprinting
is classically defined as the differential expression of the paternal or maternal allele of a
small set of genes. Among the 40 or so known imprinted genes, some such as H19, Igf2r
and p5 7kip2, are expressed when inherited from the mother while others, such as Snrpn,
Pegl and Peg3, are expressed when inherited from the father.
DNA methylation patterns are established and maintained during development by
three distinctive DNA cytosine methyltransferases (Dnmtl, Dnmt3a, and Dnmt3b) (Bird
and Wolffe 1999). Recently, a third member of the Dnmt3 family, the DNA
methyltransferase-like protein Dnmt3L, was shown to be required for the establishment
of maternal methylation imprints in mouse (Bourc'his, Xu et al. 2001; Hata, Okano et al.
2002). Although Dnmt3L lacks the conserved residues known to be involved in DNA
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methyltransferase activity and is inactive on its own, it has been shown that Dnmt3L
physically interacts with Dnmt3a and Dnmt3b and is necessary for maternal and paternal
de novo methylation in gametogenesis (Bourc'his, Xu et al. 2001; Hata, Okano et al.
2002; Bourc'his and Bestor 2004; Kaneda, Okano et al. 2004; Suetake, Shinozaki et al.
2004; Hata, Kusumi et al. 2005).
Dnmtl is believed to function primarily as a maintenance DNA methyltransferase
that is required for stable inheritance of tissue-specific methylation patterns. Inactivation
of Dnmtl in mice leads to global loss-of-methylation and bi-allelic expression or
silencing of imprinted genes (Li, Bestor et al. 1992; Li, Beard et al. 1993; Caspary,
Cleary et al. 1998). Thus, DNA methylation is believed to be the epigenetic mechanism
that controls imprinting in mammals. The presence of differentially methylated regions
(DMRs) between paternal and maternal alleles in almost all imprinted genes provides a
molecular basis for the regulation of allele-specific expression (Neumann and Barlow
1996; Ferguson-Smith and Surani 2001). DNA methylation is a reversible epigenetic
process that can be reprogrammed during embryogenesis and gametogenesis (Reik, Dean
et al. 2001). Parental methylation imprints are erased in the primordial germ cells during
embryogenesis and are re-established during gametogenesis in male and female germ
cells independently (Reik and Walter 2001). In addition, the DMRs of imprinted genes
must resist the genome-wide demethylation that takes place soon after fertilization and
the wave of de novo methylation that occurs after implantation (Monk, Boubelik et al.
1987).
Imprinted genes appear to function in a wide range of developmental processes
such as the regulation of embryonic growth, placenta function, and maternal behavior.
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While various theories have been proposed to explain the evolution and function of
imprinting (Moore and Haig 1991) (Barlow 1995) (Jaenisch 1997) (Tilghman 1999), the
'parental conflict' hypothesis by Moore and Haig is the most widely accepted. The
'parental conflict' proposes that imprinting arose in polyandrous (multiple fathers per
litter) mammals as a result of a conflict between the father and the mother over the
allocation of maternal resources to the offspring. It is envisioned that the father's
objective is to achieve maximal flow of nutrients to its offspring to effect maximal
growth. Thus, many of the paternally-expressed imprinted genes are involved in
placental growth or function. Conversely, the mother's objective is to spread resources
evenly to her offspring. Ultimately, this tug of war results in a growth-rate that is a
compromise between the two parental objectives. The 'parental conflict' hypothesis
makes a specific prediction that if imprinting were eliminated from both the paternal and
the maternal genomes, there would be no ill effects and the 'imprint free' genome would
support normal embryonic development (Moore and Haig 1991; Jaenisch 1997).
In this study, we have examined the effect of loss-of-imprinting (LOI) on
embryonic development by using conditional alleles of Dnmtl to remove the imprinted
methyl marks from the genome of both biparental (wild-type) and androgenetic (AT)
embryonic stem (ES) cells. The developmental potential of these imprint-free (IF) cells
were then examined by tetraploid complementation and chimera studies. Our analysis
showed that LOI was embryonic lethal in a biparental background and caused an
overgrowth phenotype that could not be rescued by reactivating expression of the
negative growth regulator, Ig2r. In an AT background, LOI extended development
compared with unmanipulated AT-embryos and restored pluripotency to IFAT-ES cells.
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However, IFAT-embryos died at an earlier stage than biparental IF-embryos, suggesting
that other mechanisms may exist to maintain non-equivalency between the paternal and
maternal genomes.
3.4 Results
3.4.1 Imprint free and Control ES cells.
We have previously reported a technique to generate IF-ES cells by sequentially
inactivating and then restoring the expression of conditional alleles of Dnmtl using cre
and flpe recombinases (Holm et al., 2005). This strategy results in global LOI while still
preserving the genome-wide methylation of repetitive DNA elements. As a control, the
ES cells were exposed to flpe then cre (in the reverse order) resulting in the preservation
of Dnmtl activity and normal methylation patterns (Fig 3.1).
3.4.2 Effect of LOI on embryogenesis
In our earlier study, the effect of LOI on embryogenesis was not examined. To
investigate this, embryos derived from the IF-ES cells were generated by tetraploid
complementation. No full-term pups were ever recovered from these experiments,
suggesting that LOI resulted in embryonic lethality. Timed dissections were then
performed to determine the developmental stage the IF-embryos were achieving. IF-
embryos with a normal gross morphology were found from E8.5-10.5. At E1 1.5, IF-
embryos displayed mixed characteristics of both E10.5 and El 1.5 wild-type embryos
(Fig 3.2; Table 3.1). For example, IF-embryos at this stage displayed retina
pigmentation and limb bud development that was characteristic of the E 1.5 stage.
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Figure 3.1 Generation of IF-ES cells
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Figure 3.1
Schematic representation of the steps used to create the IF-ES cells. Red and blue
indicate the Dnmt1 genotype. CTL-ES cells were generated by reverse exposure to
the recombinases.
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Figure 3.2 Development of embryos with different epigenetic status.
Figure 3.2 Development of embryos derived from ES cells with different epigenetic status
using tetraploid complementation.
(A) Embryo derived from CTL-ES cells at day E11.5. (8) Embryos derived from IF-ES cells
at day E10.5-11.5. (C) Embryo derived from PT-ES cells at day E9.5-10.5. (D) Embryo
derived from AT-ES cells at day E8.5. (E) Embryo derived from Dnmt1 null (DN) 2Frt/1 LoxP
ES cells at day E8.5.
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However, the overall morphology of IF-embryos at E 11.5 more closely resembled that of
an E10.5 biparental wild-type embryo, although IF-embryos were qualitatively larger
than expected for the E10.5 stage. The larger size of IF-embryos may be indicative of an
overgrowth phenotype or alternatively the IF-embryos may have stalled their
development between E10.5 and El 1.5 but continued to increase in size. Dissections of
IF-embryos after the E1 1.5 time point revealed no further advancement in embryonic
development and necrosis became evident at E14.5. We conclude from these data that
embryos lacking imprinting fail to develop beyond the E10.5-11.5 stage, thus indicating
that imprinting is essential for embryogenesis.
IF-embryos represent a state in which the methyl marks of imprinting are
removed. We next wanted to compare the embryonic lethal phenotype of IF-embryos to
those of embryos with different states of genome methylation. To do this, we generated
ES cells with uniparental patterns of imprinting (parthenogenetic and androgenetic), as
well as ES cells that were completely devoid of imprinting and repetitive sequence
methylation (Dnmtl null embryos). To create the parthenogenic (PT) ES cells, we first
generated PT blastocyts by activating oocytes with strontium and cytochalasin B, and
then used these to derive an ES cell line with maternal-only imprinting. Tetraploid
complementation was then used to make PT-embryos from these parthenogenetic ES
cells. Timed dissections revealed that PT-embryos survived to E9.5-E10.5, as previously
reported (McGrath and Solter 1984; Surani, Barton et al. 1984; Spindle, Sturm et al.
1996), and appeared grossly normal (Fig 3.2; Table 3.1).
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Table 3.1
Embryos generated from different epigenetic states
Status of embryonic Number of embryos
imprinting. jexamined.
Generated by tetraploid complentation
Biparental-IF (IF) 19
Androgenetic (AT) 8
Androgenetic-IF (IFAT) 4
Parthenogenetic (PT) 7
Dnmtl null 2F/1L (DN) 3
Day E13.5 chimeras
Biparental-IF (IF) 29
Biparental-CTL (CTL) 28
Androgenetic (AT) 9
Androgenetic-IF (IFAT) 15
To generate androgenetic (AT) ES cells, we removed the maternal pronucleus from a
fertilized egg and then fused the zygote to a second male pronucleus that was
transplanted just under the zona pellucida. AT-embryos generated by tetraploid
complementation were found to develop up to the E8.5 stage, but not beyond this time
point (Fig 3.2; Table 3.1).
To create Dnmtl-null embryos (DN), the ES cell line carrying the cre- and flpe-
conditional alleles of Dnmtl was exposed to cre alone (resulting in inactivation of Dnmtl
activity), and then used as a source of cells for tetraploid complementation. Similar to
the androgenetic embryos, DN-embryos developed up to E8.5 but not beyond (Fig 3.2;
Table 3.1), suggesting that the loss of genome-wide DNA methylation mediated by
Dnmtl perturbs embryogenesis to a similar extent as having a paternal-only pattern of
imprinting. Taken together, these data highlight the importance of correct DNA
methylation patterns for embryonic development and indicate that the severity of
developmental defects caused by altered DNA methylation patterns follows the
phenotypic order of DN=AT>PT>IF.
3.4.3 LOI and chimera studies
Chimera studies have shown that cells with uniparental patterns of imprinting
contribute unequally to tissues in the embryo, suggesting that the imprint status of the ES
cell affects its pluripotency (Thomson and Solter 1988; Allen, Logan et al. 1995). To
determine whether LOI affects ES cell pluripotency, IF-ES cells (carrying a LacZ
reporter) were injected into biparental wild-type blastocysts and chimeric embryos at
E13.5 were analyzed. Staining for LacZ activity revealed that IF-ES cells contributed to
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Figure 3.3 IF-Chimera studies
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Figure 3.3 IF-Chimera studies.
(A) Day E13.5 chimeric embryos cut in sagittal section and stained for the presence of
the IF and CTL- ES cell marker ~galactosidase. (8) Teratoma tumor formation from
WT/IF ES cells immunohistochemically stained for GFP. M= Mesodermal (Cartilage);
En= Endodermal (Glandular epithelium/GI); Ec= Ectodermal (Neural) (C) IF-Embryos
are a larger size. Weight distribution of IF and CTL chimeric animals. P values: * =
2.1 x 10-5, ** = 6.8 x 10-5, t = 5.6 x 10-3.
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all tissues of the chimera with the same level of efficiency as control ES cells (Fig 3.3A;
Table 3.1). To explore this more closely, we injected wild-type and IF-ES cells (carrying
the GFP reporter) under the skin of severe combined immunodeficient (SCID) mice and
assayed teratoma formation. As an internal control, to ensure that the teratomas were
capable of generating tissue derivatives from all three germ layers, a 1:1 mixture of IF-ES
cells and wild-type ES cells were injected into the SCID mice. After 14 days, the
teratomas were dissected, sectioned, and immunohistochemically stained for GFP. The
IF-ES cells, like the co-injected wild-type ES cells, were found to give rise to tissue
derivatives from all three germ layers, including glandular epithelial cells (endoderm),
neuronal cells (ectoderm) and cartilage (mesoderm; En, Ec and M in Fig 3.3B). Taken
together, these results indicate that LOI does not result in a loss of ES cell pluripotency or
biased contribution.
In the course of performing the IF chimera experiments, it was noticed that the
greater the number of IF-ES cells that contributed to the chimera, the larger the embryos
appeared (Fig 3.3A). To more accurately quantitative this, either a small (4-5) or large
(10-12) number of IF-ES cells or control ES cells were injected into wild-type blastocysts
and the resulting embryos were weighed at E13.5. Regardless of whether 4-5 or 10-12
IF-ES cells were injected, there was a statistically significant increase in the weight of
chimeric IF-embryos compared with chimeras derived from control ES cells (Fig 3.3C).
3.4.4 Reactivation of the Ig/2r allele in IF-embryos
We and others have previously found that despite a loss of the methyl marks that
maintain imprinting, the Ig/2 locus becomes variably re-methylated and therefore re-
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Figure 3.4 Reactivation of Igf2r expression
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Figure 3.4 Reactivation of Igf2r expression
(A) Confirmation of Igf2r expression by northern blot analysis of RNA extracted from
Day 7 retinoic acid differentiated CTL, IF+lgf2r and IF-ES cells. (B) Targeting con-
struct for reactivation of Igf2r allele (Wutz et al 1997). B=BamH1, H=HinDIII,
E=EcoRI. (C) Development of embryos derived from both IF and IF+lgf2r ES cells
using tetraploid complementation. IF embryonic development to day E10-11.5.
IF+lgf2r embryonic development to day E12.5.
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expressed in IF cells (Tucker, Beard et al. 1996) (Biniszkiewicz, Gribnau et al. 2002)
(Holm et al., 2005). Consistent with this, we found expression of Igf2 in IF-embryos,
contrary to what one would expect in a LOI state (data not shown). In contrast, the Igf2r
locus, which encodes a negative regulator of Igf2 that acts by sequestering excess ligand,
was not expressed in IF-embryos, as expected (Fig 3.4A). Based on these observations,
we hypothesized that the overgrowth phenotype associated with LOI may be related to an
imbalance in the expression of Igf2 and Igf2r. To test this, we removed the differentially
methylated region (DMR) in intron two of the Igf2r locus by gene targeting in IF-ES cells
(Fig 3.4B). Deletion of this DMR is known to result in re-activation of Igf2r expression
(Wutz, Smrzka et al. 1997). Successful re-activation of monoallelic Igf2r expression in
the targeted IF-ES cells (referred to herein as IF+Igfr2) was confirmed by Northern blot
analysis following retinoic acid-induced differentiation (Fig 3.4A). The IF+Igfr2 ES
cells were then used to generate embryos by tetraploid complementation. No full-term
pups were recovered from these experiments and timed dissections revealed that the
IF+Igfr2 embryos developed until E12.5, before becoming necrotic and partially
reabsorbed (Fig 3.4C). Grossly, the IF+Igfr2 embryos displayed an overgrowth
phenotype similar to IF-embryos (data not shown). To more accurately quantitate this,
we made IF+Igfr2 chimeric embryos and compared their weights with IF-ES and control
ES chimeras. This analysis revealed no significant statistical difference between the
weights of IF+Igfr2 and IF chimeras (Fig 3.5A). In order to obtain further evidence that
the growth of IF cells was unaffected by re-activating Igf2r expression, we derived
murine embryonic fibroblasts (MEFs) from IF and IF+Igfr2 embryos and examined their
growth rates in vitro. IF and IF+Igfr2 MEFs were found to have similar growth rates to
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Figure 3.5 Growth characteristics of IF+lgf2r chimeric embryos and MEFs
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Figure 3.5 Growth characteristics of IF+lgf2r chimeric embryos and MEFs
(A) Increased body weight of E13.5 IF chimeric embryos is not altered by reactivation
of Igf2r expression. P values: * = 8.0 x 10-3, t = not significantly different. (B) Growth
rate of IF, IF+lgf2r and CTL murine embryonic fibroblasts.
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each other, although these rates were markedly higher than that of control MEFs (Fig
3.5B). We conclude from these experiments that an imbalance between Ig2 and Igf2r
expression is not the primary cause of the overgrowth phenotype or the lethality observed
in the IF-embryos. However, given that re-activation of Igf2r expression in IF-embryos
extended their development from E 11.5 to E12.5, it is likely that Igf2 signaling does
contributes to the embryonic phenotype of IF-embryos.
3.4.5 Imprint free androgenetic embryos
If DNA methylation is the sole mechanism responsible for maintaining
imprinting, then erasing the methyl marks associated with imprinting in AT-ES cells
would be expected to extend embryonic development from E8.5 to E1 1.5. To test this,
Dnmtl expression was sequentially inactivated and then re-activated in AT-ES cells,
according to the strategy used to generate IF-ES cells. IFAT-embryos were then derived
by tetraploid complementation, and timed dissections performed to determine the
developmental stage reached by IFAT-embryos. Unlike AT-embryos, IFAT-embryos
underwent turning and developed relatively normally to the E9.5-10.5 stage (Fig 3.6A;
Table 3.1). However surprisingly, the IFAT-embryos failed to develop beyond this stage
and were found necrotic and partially reabsorbed at later time points. This finding,
contrary to expectations, suggests that a mechanism/s other than DNA methylation are
responsible for the parent-of-origin specific patterns in imprinted gene expression. At
present, the nature of such a mechanism is unclear.
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Figure 3.6 Generation of AT and ATIF embryos
A
B AT IFAT
•
Figure 3.6
(A) Development of embryos derived from both AT and IFAT ES cells using tetraploid
complementation. AT= day EB.5 and IFAT= day E9.5-10.5. (B) Restricted contribu-
tion of AT ES cells to chimeric day E13.5 embryos and unbiased contribution of IFAT
ES cells to day E13.5 embryos.
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It has previously been demonstrated that AT cells display a biased tissue
contribution in chimeric embryos (Thomson and Solter 1988). We therefore examined
whether IFAT-ES cells displayed a similar developmental bias. IFAT-ES cells, carrying
the GFP reporter, were injected into wild-type blastocysts and tissue contribution was
examined at E13.5 by immunohistochemical staining for GFP protein. Unlike AT-ES
cells, which showed a bias towards striated muscle, skeletal elements, fetal liver and
hypothalamus, IFAT cells contributed equally to all tissues in the E13.5 embryo (Fig
3.6B; Table 3.1). Thus, LOI in AT-embryos was sufficient to rescue AT-ES cell
pluripotency, consistent with the imbalanced methylation state of AT cells being
responsible for their developmental bias.
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3.5 Discussion
In this study we have addressed whether the DNA methyl marks associated with
maintaining imprinting are required for normal embryonic development. As
comparisons, we also examined the developmental potential of three other altered
methylation states represented by parthenogenotes, androgenotes and Dnmtl null
embryos. Our analysis showed that global LOI resulted in a failure of the embryo to
develop beyond Ell.5 and induced an Igf2-independent overgrowth phenotype.
However, IF-embryos were the most advanced developmentally compared with the
uniparentally-derived embryos (AT and PT) and Dnmtl-null mutants (DN).
Understanding the functional significance of imprinting in mammals has been a
central question to the field. To date, the 'parental conflict' hypothesis provides the best
explanation for why imprinting evolved and predicts that paternally expressed genes
should promote growth and maternally expressed genes should slow it down. The most
striking examples of imprinted genes that support this hypothesis are the paternally
expressed growth factor, Igf2 and its negative regulator Igf2r, which is maternally
expressed. Mouse embryos deficient in Igf2 show a 40% reduction in growth, whereas
Igf2r-null embryos exhibit an overgrowth phenotype and perinatal lethality (DeChiara,
Efstratiadis et al. 1990; Lau, Stewart et al. 1994; Wang, Fung et al. 1994). Remarkably,
the double mutant is normal-sized and viable (Ludwig, Eggenschwiler et al. 1996). Such
results have led to the prediction that imprinting will be dispensable under conditions
where the imprints on both parental genomes are erased (Moore and Haig 1991)
(Jaenisch 1997). The results of this study show that IF-embryos are not viable.
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However, caution must be exercised when interpreting these results, as a number
of caveats exist. Firstly, at least one imprinted locus, Igf2, is known to undergo
'methylation drift' and can become re-activated following loss of the methylation that
maintains imprinting (Tucker, Beard et al. 1996; Biniszkiewicz, Gribnau et al. 2002;
Holm et al 2005). As mention above, an imbalance in the expression of Ig/2 and Igf2r
leads to embryonic overgrowth and perinatal lethality. To examine the contribution that
reactivated Igf2 expression was playing in the LOI phenotype, we reactivated Igf2r
expression in IF-embryos and demonstrated a slight increase in developmental potential
from El 1.5 to E12.5. However, restoring monoallelic expression of lgf/2r failed to rescue
the IF embryonic overgrowth phenotype. We conclude from this result, that the Igf2
pathway makes only a small contribution to the phenotype of IF-embryos and other
imprinted genes must be primarily responsible. Although we cannot completely rule-out
that other imprinted loci do not become reactivated in the same way as Ig12, our previous
microarray analysis of IF murine embryonic fibroblasts suggests that the phenomenon of
methylation drift is unique to the Ig/2 locus (Holm et al 2005). Secondly, imprinting is
an adaptation that probably arose fairly recently in mammalian evolution, as non-
mammalian vertebrates possess most, if not all, of the orthologues found imprinted in
mammals but they express them biallelically (Tilghman 1999). Therefore, it could be
argued that an imprint-free state should be defined as biallelic expression at all imprinted
loci, thus reflecting the 'ancestral' ground state of the mammalian genome. For this
study, we have defined an imprint-free state as one in which the DNA methyl marks
associated with imprinting are erased. However, due to the complexities of how different
DMRs function, several imprinted genes, including the negative growth regulator GrblO
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and the cell cycle inhibitorp57 kip2, are silenced in response to LOI (Holm et al 2005). As
a result, it is unlikely that the IF-embryos generated in this study exhibit biallelic
expression at all imprinted loci and therefore do not represent the 'ancestral' ground state.
The silencing of some imprinted genes will undoubtedly contribute to the LOI phenotype.
For example, GrblO knockout mice display similar characteristics to IF-embryos,
including an Igf2-independent overgrowth phenotype that is first detectable at E12.5
(Charalambous, Smith et al. 2003). Thirdly, the role of the placenta must be considered
when interpreting the phenotype of IF-embryos. When using tetraploid complementation
as a means of generating embryos, the IF-ES cells give rise solely to the embryo proper,
whereas the normally imprinted tetraploid cells contribute to the placenta (Eggan, Rode
et al. 2002). Because the transfer of nutrients from the placenta to the embryo is critical
for normal growth, and given that imprinted genes are known to regulate placental size
and function, it is possible that a regulatory imbalance between the normally imprinted
placenta and the IF-embryo contributes to the IF phenotype. One strategy to overcome
this in future studies would be to perform nuclear transfer experiments with IF-ES nuclei
and generate a cloned embryo that would lack imprinting in both the embryo proper and
extraembryonic tissues.
One of the most interesting results of this study is the observation that
androgenetic embryos deficient in imprinted methyl marks are not developmentally
equivalent to biparentally-derived IF-embryos. This finding raises the possibility that
other mechanisms in addition to DNA methylation exist to maintain parent-specific
expression patterns. The recent observation that Dnmt3L/Dnmt3a complexes can interact
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with polycomb- and thrithorax-like proteins (Burgers, Fuks et al. 2002), suggests that one
such mechanism may involve stable changes in chromatin organization.
In summary, the results of this study indicate that although removing the DNA
methyl marks associated with imprinting confers the greatest developmental potential to
the embryo compared with the imbalanced uniparental states of androgenotes and
parthenogenotes, it is not sufficient for viability. Whether this is due to a failure to
restore biallelic expression at every imprinted locus, or whether it is caused by the
existence of other non-DNA methylation mechanisms for maintaining imprinting is not
clear at present and requires further study.
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3.6 Experimental Procedures
3.6.1 Generation of imprint free and control ES cells.
The 2-Frt Flanked Dnmtl Inactive Allele was constructed as described in Holm et
al 2005. Imprint free (IF) and Control (CTL) embryonic stem (ES) cells were generated
as previously described (Holm et al 2005).
3.6.2 Reactivation of monoalleleic Igf2r expression in IF-ES cells.
Monoallelic expression was restored to IF-ES by targeted mutation of the DMR
within intron2 of the Igf2r gene as described (Wutz, Theussl et al. 2001). Briefly IF-ES
cells were cultured as previously described (Li, Bestor et al. 1992) and 10x106 cells were
electroporated with 30 mg NotI linearized R2DNT targeting vector using a Genepulser
(Biorad) set to 960 mF and 200 V, and selected in Hygromycin (Sigma) for 8 days.
Targeting of R2DNT was screened by Southern blot analysis. Subsequently, the selection
cassette was removed by transient transfection with 30 mg Cre expression plasmid (Gu,
Marth et al. 1994) and selection in medium containing 2 mM gancyclovir.
3.6.3 Generation of imprint free androgenetic and androgenetic ES cells.
All experiments on live vertebrates were preformed in accordance with relevant
institutional and national guidelines and regulations. Massachusetts Institute of
Technology's committee on animal care has approved the experiments and has confirmed
that all experiments conform to the relevant regulatory standards. The most recent
review and approval received on November 4th 2004.
132
Male mice that were either heterozygous for the inactive 2Frt Dnmtl allele or
homozygous for the conditional 2LoxP Dnmtl allele (Jackson-Grusby, Beard et al. 2001)
were crossed to wild-type C57B6 female mice. Fertilized embryos were dissected at
E0.5, and cultured until pronuclear formation. The male pronuclear was removed from
embryos derived from the mating of female C57B6 mice to male mice heterozygous for
the 2Frt Dnmtl allele. The male pronucleus was placed under the zona of embryos
generated from crossing female wild-type C57B6 mice to male mice homozygous for the
conditional 2LoxP Dnmtl allele, in which the female pronucealus had already been
removed. Electric current was passed across the embryo and male pronuclus causing
membrane fusion. Reconstructed androgenetic embryos were cultured until the
blastocyst stage, and explanted for ES cell line derivation as described (Hochedlinger and
Jaenisch 2002). ES cells were cultured as previously described (Li, Bestor et al. 1992).
The androgenetic ES cell line tested positive for both the 2Frt and the 2LoxP Dnmtl
alleles. These cells were exposed to Cre-recombinase and Flpe-recombinase through
lipofectamine mediated, transient transfection as previously described.
3.6.4 Derivation of parthenogenetic ES cells.
Metaphase II oocytes were isolated as previously described (Hochedlinger and
Jaenisch 2002). Briefly, oocytes were collected from the oviducts of superovulated
B6D2F1 female mice (Taconic) and stored in KSOM embryo culture media (Specialty
media). Embryos were activated for 6 hours in calcium-free MCZB medium in the
presence of 10 mM Sr2+ and 5 g/mL of cytochalasin B before replacement by KSOM.
Parthenogenetic embryos were cultured until the blastocyst stage, and explanted for ES
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cell line derivation as described (Hochedlinger and Jaenisch 2002). ES cells were
cultured as previously described (Li, Bestor et al. 1992).
3.6.5 Derivation of primary embryonic fibroblast cells from ES cells.
MEFS were derived from day 13.5 embryos obtained by injecting ES cells into
wild-type BDF1 blastocysts and implanted into foster mothers. MEFs derived from
chimeric embryos were selected for two passages with the appropriate antibiotics. MEFs
were frozen at passage 2 or 3 and with the exception of long-term culture were used for
all experiments before passage 6. Only pure populations were used as assayed by
genomic southern or PCR. MEFs and 293T ecotrophic packaging cell line were grown in
DMEM supplemented with 10% FBC, 5mM Glutamine and penicillin/streptomycin. All
the cells used tested negative for mycoplasma.
3.6.6 Growth curves.
All experiments were repeated at least 3 times using cells from a minimum of 5
different fetuses for each genotype. For growth curves 3 x 104 cells were plated into 12
well dishes and fed every 2ndday (Sage, Mulligan et al. 2000).
3.6.7 Production of mice.
For tetraploid blastocyst injections, two-cell embryos derived from B6D2F1
females were first electro-fused in 0.3 M mannitol/0.3% BSA using the LF-101 cell
fusion instrument (Protech International). For diploid blastocyst injections, fertilized
zygotes were isolated from the oviducts of day 0.5 pregnant B6D2F1 allowed to develop
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to the blastocyst stage in culture. Between five and 15 ES cells were injected per
blastocyst. These were transferred into day 2.5 pseudo-pregnant B6D2F1 recipient
females. C-sections were performed at timed intervals for embryos derived from
tetraploid blastocyst. Chimeric animals were sacrificed at day E13.5 and embryos were
removed at necropsy and either fixed in formalin for sectioning and GFP
immunihistochemistry or stained for the presence of the -galactosidase gene.
3.6.8 Teratoma tumor formation.
To test pluripotency, exponentially growing ES cells were resuspended in PBS
and 1 x 106 cells were injected subcutaneously into SCID mice. Tumor development was
monitored for 14 days and the tumor removed at necropsy and fixed in formalin.
3.6.9 Histology.
Normal and tumor tissue samples were fixed in 10% buffered formalin for 24 h
and embedded in paraffin. Sections (5 gm) were used for immunohistochemical analysis.
Immunostaining was performed using an avidin-biotin immunoperoxidase assay. Primary
antibody anti-GFAP (1:500; Dako). Sections were incubated with primary antibodies for
24 h and subsequently with biotinylated secondary antibodies (Vector Laboratories) for
30 min, followed by incubation with avidin-coupled peroxidase (Vector Laboratories) for
30 min.
3.6.10 t-Galactosidase detection.
Dissected whole embryos were fixed in 0.5% glutaraldehyde and 4%
paraformaldehyde in PBS for 12 hours and incubated with the substrate 5-bromo-4-
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chloro-3-indolyl-13-D-galactoside (Xgal) for 4 hours. The presense of the P-galactosidase
is denoted by a blue ferrocyanide precipitation (Holt and O'Sullivan 1958).
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Chapter 4:
Perspectives and Conclusions
The goal of this study was to generate imprint-free cells by sequentially
inactivating and then reactivating Dnmtl. While our data to date are consistent with the
generation of an imprint-free state, there are a number of important caveats to consider.
Firstly, the ES cells carrying the conditional alleles of Dnmtl were heterozygous for the
expression of Dnmtl. Thus, we cannot rule-out that some of the effects observed with IF
cells were not the result of haploinsufficiency for Dnmtl. However arguing against this,
numerous studies both published and unpublished have shown that Dnmtl heterozygotes
are normal, healthy animals that are equivalent to wild-types (Li et al 1992; 1993).
Secondly, we cannot be completely sure that the restoration of global DNA methylation
following reactivation of Dnmtl did not inadvertently affect the expression status of non-
imprinted genes. Such perturbations may have contributed to the embryonic lethality and
cancer phenotype observed in the IF mice and may have also been 're-set' following
passage through the germline. While our microarray analysis of IF-MEFs did not
identify any abnormalities in non-imprinted gene expression, we cannot rule-out that
altered gene expression might have been present in other cell types or embryonic stages.
Thirdly, we detected abnormal expression at the Igf2/H1 9 locus due to de novo
remethylation. At present, we do not know whether there are other imprinted genes that
undergo a similar 'methylation drift'. Therefore, it is possible that the IF phenotype may
be influenced by imbalanced imprinting at critical imprinted loci that control the cell
cycle or embryonic growth.
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Despite these caveats, if we assume that the phenotypes observed, e.g. embryonic
lethality, altered growth characteristics, resistance to TGF-13, immortality, and a
propensity to form tumors in the adult are caused by a bona fide LOI, then the key
question that remains is: What are the imprinted genes responsible for these effects?
While the answer to this question can only be obtained from further research, it is
possible to speculate about potential candidate genes.
4.1 LOI and growth inhibition by TGFP
LOI induced MEFs to become refractory to the cytostatic effects of TGFP. A
failure to undergo cell cycle arrest in response to TGFP is a hallmark of cancer cells,
however, the exact mechanism by which this is achieved is still not fully understood. In
primary epithelial cells, TGFfi3 triggers cell cycle arrest by up-regulating cytostatic
proteins such as the cyclin dependent kinase (CDK) inhibitors, p1 5 Ink4b and p21CiPl, while
down-regulating growth promoting transcription factors such as c-Myc and Id family
members (Chen, Kang et al. 2002; Kang, Chen et al. 2003; Kowanetz, Valcourt et al.
2004). More recently, embryonic studies have suggested that p53 may participate in the
TGFfipathway and a direct interaction between p53 and Smad2 and Smad3, two
downstream effectors of TGF3 signaling, has been demonstrated (Cordenonsi, Dupont et
al. 2003). Furthermore, p53-null MEFs display a defective cytostatic response to TGF3
and a concomitant inability to induce p21CiPl expression, a known p53 target (Cordenonsi,
Dupont et al. 2003). Theses observations provide an attractive explanation for the loss of
TGFP3-induced growth inhibition seen with IF-MEFs, given that these cells have
abnormally low levels of p53 protein. Wild-type levels of p21CiPl protein were detected
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in the IF-MEFs by Western blot analysis. However, these cells were not treated with
TGFI3, therefore it is not known whether they show an attenuated ability to induce p2 1Cipl
in response to TGFf3 exposure. Further studies of IF-MEFs and their cellular response to
TGF3 are needed to investigate this issue. For example, it should be possible to restore
p53 expression to IF-MEFs by viral transfection and then examine their response to
TGFPi treatment.
An alternative possibility is that the growth-inhibiting effects of TGFI3 are
defective in IF-MEFs because of an imprinted gene that is no longer expressed in these
cells. One such candidate is p57K ip2, which like p2 1Cipl, belongs to the Cip/Kip family of
cyclin-dependent kinase inhibitors (CDKIs) (Hatada and Mukai 1995). p5 7Kip2 is a
maternally transcribed gene that is regulated by an imprint control region that needs to be
methylated in order for the locus to be expressed (Diaz-Meyer, Day et al. 2003). Thus,
in cells deficient in imprinting, it is predicted thatp 57KiP2 transcription would be silenced.
Consistent with this, the microarray data of IF-MEFs showed an absence of p5 7Kp2
expression. In the hematopoietic system, the cytostatic effects of TGFP are mediated by
p57Kip2 (Scandura, Boccuni et al. 2004) and in humans, mutations in p57 KiP2 have been
found in patients with Wiedemann-Beckwith syndrome, a human overgrowth disorder
that is accompanied by an increased risk of embryonal tumors (Hatada, Inazawa et al.
1996) (Thompson, Reese et al. 1996). Given that p57KiP2plays a role in both the growth-
suppressive pathway downstream of TGFi and causes an embryonic overgrowth
phenotype, two features also associated with LOI, it is tempting to speculate that loss of
p5 7 Kip2 expression may be major contributor to the LOI phenotype.
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4.2 The role of Grb10 in regulating mitogenic growth.
The GrblO0 gene, which is maternally expressed in mice, is another likely
candidate for contributing to the LOI phenotype. GrblO encodes a cytoplasmic adapter
protein that modulates coupling to a number of receptor tyrosine kinases (Riedel 2004).
In addition, GrblO has also been found to interact with non-receptor tyrosine kinases such
as Tec and Bcr-Abl, and other cellular signaling molecules such as Raf-1 and the mitogen
activated protein (MAP) kinase kinase, MEK (Lim, Riedel et al. 2004). Disruption of the
active maternal allele results in an embryonic overgrowth phenotype in which the mutant
mice are 30% larger than normal (Charalambous, Smith et al. 2003). These results
established Grb 10 as a potent growth inhibitor. Although Grb1 0 is capable of interacting
with, and suppressing, Igf-stimulated cell signaling and DNA synthesis, genetic
experiments in vivo demonstrated that the overgrowth phenotype of Grb 10O null mice was
independent of Igf2 (Dufresne and Smith 2005) (Charalambous, Smith et al. 2003).
These findings suggest that loss of GrblO function leads to an activation of fetal growth
pathways. The microarray analysis of IF-MEFs revealed a marked downregulation of
GrblO expression. As found forp5 7Kip2 above, the DMR controlling GrblO expression
shows a maternal methylation mark that is likely needed for transcription. Thus, in an IF
state, neither maternal nor paternal alleles of GrbJO are expressed, and IF cells would be
expected to behave like GrblO null cells. The finding that IF-chimeric embryos were
40-50% larger than control chimeras is consistent with loss of Grb10 contributing to the
LO1 overgrowth phenotype. The importance of GrblO in the LOI phenotype could be
directly tested in future studies by restoring GrbJO expression either in vitro (eg MEFs)
or in vivo.
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4.3 Role of Igf signaling and mitogenic growth
Signaling of Igfl and Igf2 through the Igflr is an important pathway for fetal
growth, as highlighted by mouse knockout studies that have shown dwarfing phenotypes
following loss of each locus (DeChiara, Efstratiadis et al. 1990), (Liu, Baker et al. 1993),
(Baker, Liu et al. 1993)). In addition, stimulation of the Igf pathway has been implicated
in the formation of numerous cancers (Feinberg and Tycko 2004). Thus, increased Igf
signaling in response to LOI is an obvious candidate for contributing to the abnormal
growth characteristics of IF cells. In IF-embryos however, reactivation of monoallelic
Igf2r expression had only a subtle effect on developmental potential and failed to rescue
the overgrowth phenotype. In addition, the re-activation of Igf2r in IF-MEFs had no
effect on growth rate. It is possible that the level of restored Igf2r expression in the IF
cells is just not sufficient to balance out the amount of Igf2 being generated. In which
case, a better test of the involvement of the Igf pathway in the IF phenotype would be to
target the Igf2 locus directly. Alternatively, the Igf pathway may not be a major player in
the IF phenotype at the developmental time points examined. Evidence in support of this
comes from the finding that the overgrowth phenotype of IgJ2r mutant embryos does not
become manifest until after E13 (Ludwig, Eggenschwiler et al. 1996), whereas in this
study IF-embryos were qualitatively larger at E1 1.5. However, we cannot rule out that an
imbalance between Igf2 and Igf2r expression in IF cells is a significant contributor to the
formation of tumors in adult chimeras. In support of this, IF-MEFs in which Igf2r
expression is restored show a slight, but statistically significant, decrease in the number
of colonies that form in the foci formation assay (data not shown). To explore this
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further, it will be interesting to examine the tumorigenic potential of IF+Igf2r-ES cells in
adult chimeras.
4.4 The role of imprinting in the regulation of the tumor suppressor genes p9 "4rf and
p53
When normal primary cells are continuously passaged, they exhibit progressive
increases in the protein level of p 16Ink4a and undergo replicative senescence (Sherr 2001).
p16 In k4 a is a cell cycle kinase inhibitor that targets the CyclinD-cdk4/6 complex, thereby
preventing phosphorylation of Rb-E2F and inhibiting progression into S phase. In IF-
MEFs, p 61nk4a levels showed the expected increase in protein level as passage number
increased. However, despite the presence of high p16Ink4a levels, IF-MEFs failed to
senesce and instead were immortal. Previous studies have shown that p1 6 Ink4a is unable
to prevent Rb phosphorylation in the absence of p53 (Sherr 2001). Consistent with this,
IF-MEFs were found to have decreased levels of p53 at early passages and an absence of
protein by mid-passage. The altered protein profile of p53 in IF-MEFs correlated with
that of p21CiPl, a known downstream target of p53 and a cell cycle inhibitor of cyclinE-
cdk2 complexes (Waldman, Kinzler et al. 1995; Gartel and Tyner 1999). While low
levels of p2 1Cipl persist in IF-MEFs after continuous passage, they must not be sufficient
to induce cell cycle arrest. These data suggest that abnormal levels of p53 are responsible
for the failure of IF-MEFs to undergo replicative senescence.
p1 9 Arf is a key player in the stabilization of p53 protein that acts by binding the
p53 ubiquitin ligase, Mdm2, and relocalizing it to the nucleolus (Sherr and McCormick
2002; Vousden 2002). In the absence of p 1 gArf p53 is rapidly degraded and has a protein
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half-life of only 9-20 minutes (Harris and Levine 2005). In normal cells approaching
replicative senescence, p19Arf levels are found to increase, thus resulting in p53
stabilization and activation of downstream targets. In contrast, IF-MEFs display a failure
to upregulate p l 9 Arf protein, thus raising the possibility that the abnormal levels of p53 in
IF-MEFs are the result of defects in p 9Arf regulation.
Regulation of pl94Arf locus is not fully understood. It is known that p 9Arf
responds to stress signals but the mechanisms regulating transcription as well as post-
translational control of p1l9Af protein are currently the subject of much debate. At the
transcriptional level, there is evidence to suggest that the p19Arf promoter is regulated by
the transcription factors DMPF1, E2F, and the AP-1 members, c-Jun and Fra-1 (Inoue,
Roussel et al. 1999; Inoue, Wen et al. 2000; Rowland, Denissov et al. 2002; Ameyar-
Zazoua, Wisniewska et al. 2005). At the post-translational level, there is the possibility
that p 9 Arf may be regulated by protein degradation as both the mouse and human
proteins undergo N-terminal polyubiquitination (Kuo, den Besten et al. 2004). Stability
of p 9 Arf depends on the nucleolar protein nucleophosmin/B23, which binds to pl9Ar f
with high stoichiometry and retards its turnover. p 9 Arf mutants that do not efficiently
associate with nucleophosmin/B23 are unstable and functionally impaired (Kuo, den
Besten et al. 2004). The absence of p 9Af induction in IF-MEFs may reflect a defect in
either pl 9Arf transcriptional upregulation or enhanced protein turn-over. At present, the
identity of an imprinted gene that could be responsible for this defect is not known.
In addition to an effect on pl9 ~f, LOI may also impact on the activity of Mdm2
and thereby affect the level of p53. Stabilization of Mdm2 can occur via phosphorylation
mediated by the mitogen-induced kinase, Akt. Phosphorylation of Mdm2 inhibits its
auto-ubiquitination and subsequent degradation (Mayo and Donner 2001; Zhou, Liao et
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al. 2001). A large number of mitogenic pathways are transduced through Akt (Song,
Ouyang et al. 2005) and imprinted genes, many of which are involved in cell growth, are
likely to influence Akt activation. The best example is Grb 10, which acts as a negative
regulator of the Akt pathway by preventing the interaction of insulin receptor substrate
proteins with tyrosine kinase receptors (including Igflr; (Lim, Riedel et al. 2004)). Given
that GrblO is most likely silenced in IF-MEFs, it is not unreasonable to expect Akt
activation to be enhanced resulting in greater stabilization of Mdm2 protein. Akt
activation is also likely to be upregulated by the imbalance in Ig/2 and Igf2r expression in
IF-MEFs, which lead to increased signaling through the Igflr. Increased Mdm2
stabilization resulting from upregulated mitogenic signaling may be sufficient to alter the
rate of p53 degradation, and thereby contribute to the decreased levels of p53 in IF-
MEFs.
Taking all of these data in consideration, a model can be proposed to explain the
effects of LOI on cell growth characteristics (Fig 4.1). Based on this model, imprinted
gene products are proposed to interfere with the p53-p1 9 Aff pathway in three major ways.
Firstly, an as-of-yet unidentified imprinted gene is required for inducing p 9 Arf
expression or stabilizing its protein levels. In the absence of high levels of pl 9 AI f, Mdm2
is not inhibited, thus resulting in increased p53 ubiquitination and degradation. Secondly,
Mdm2 activity is further enhanced by increased stimulation of mitogenic pathways
resulting from an imbalance in Ig/2 and Igfr2, and a loss of Grbl 0 expression. The loss of
p53 in IF-MEFs is then expected to make these cells refractory to the growth-suppressive
effects of TGFi, as induction ofp 2 1cip l is dependent on p53.
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Figure 4.1 Model of imprinted gene regulation in the cell cycle
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Figure 4.1 Model for imprinted gene regulation in the cell cycle.
Simiplified model illustrating the regulatory interactions between proteins
involved in the G1/S and G2IM phase transition. The proposed involvement of
imprinted gene products are shown in red and are postulated to influence the con-
trol of the cell cycle in the following way: (1) an as of yet unidentified imprinted
gene product is involved in the upregulation of p19Arf expression or protein stabil-
ity, (2) Igf2, Igf2r and Grb10 regulate mitogenic signaling through Aid, which is
involved in stabilizing Mdm2, (3) p57K1p2 is a member of the CiplKip family of
cyclin-dependent kinase inhibitors and is proposed to playa role in TGFp induced
senescence. Adapted from Dupont et al 2004.
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The loss of p53 in IF-MEFs is then expected to make these cells refractory to the growth-
suppressive effects of TGF3, as induction of p21c iC Pl is dependent on p53. Similarly, loss
of expression of the related cell cycle inhibitor, p 5 7 Ki p 2 , may also contribute to the failure
of IF-MEFs to undergo cell cycle arrest and provides the third involvement of an
imprinted gene in the IF phenotype.
4.5 Imprinting and embryonic development.
In this study we have shown that removal of the methylation that maintains
imprinting in ES cells leads to an inability to support embryonic development in
tetraploid complementation experiments. One predication from the Haig theory is that
the elimination of imprinting from both the paternal and the maternal genomes would not
be deleterious to the developing embryo, as the resulting effects would cancel each other
out (Moore and Haig 1991; Jaenisch 1997). We have assumed that because differential
methylation maintains imprinted gene expression, selective removal of this methylation
would generate an imprint-free state, thus permitting a direct test of the Haig hypothesis.
So, does the failure to generate live IF mice argue against the Haig hypothesis? Likely
not because a number of caveats need to be considered when interpreting our results.
First, we did not measure the methylation status of all imprinted genes, therefore we
cannot rule-out that some loci escaped the erasure of DNA methyl marks by our
conditional Dnmtl strategy. Second, it is possible that the embryonic lethality of IF-
embryos is the result of a 'bystander effect'- this refers to the notion that some
imprinted genes may have evolved an additional function, downstream target, or protein
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interaction that plays no part in the parent-offspring conflict but results in embryonic
lethality when disrupted following LOI. Third, DNA methylation may not be the only
mechanism that maintains imprinting. Our observation that androgenetic embryos
stripped of their imprinted methyl marks were not developmentally equivalent to
biparental IF-embryos, suggests that other mechanisms exist to control imprinted gene
expression. One speculative possibility is that imprinting is also regulated by changes of
chromatin structure. In support of this, Dnmt3L/Dnmt3a complexes are known to
interact with proteins such as polycomb- and thrithorax-like factors, which are involved
in heritable changes in chromatin structure (Burgers, Fuks et al. 2002). Fourth, the
methylation mechanisms controlling expression at imprinted loci are often complex and
in some cases DNA methylation is actually a necessary prerequisite for expression. In
the cases of GrblO andp57 Kip2, expression of these genes is silenced from both parental
alleles in the absence of imprinting, rather than reverting to biallelic expression. Thus,
what we have designated as an IF state is likely a combination of biallelic expression at
some imprinted loci and no expression at others. Fifth, the IF-embryos we generated
were produced by tetraploid complementation. Therefore, the placentas of these embryos
were derived from the tetraploid cells that were correctly imprinted. The embryonic
lethality seen following LOI may be related to the fact that an imprinted placenta was
nourishing an imprint free embryo. A future experiment that could be performed to
address the importance of the placenta in the survival of IF-embryos would be to use
nuclear transfer of an IF-ES cell nuclei to generate a cloned IF-embryo. Cells from this
embryo would give rise to the embryo proper as well as contribute to the placenta, and
therefore address the effect of LOI in the placenta on IF-embryo viability.
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4.6 Future directions and perspectives on imprinting
As a result of the caveats mentioned above, our experiments cannot definitively
prove the prediction that removing imprinting will have no deleterious effects to the
embryo. It seems likely that we are a long way from achieving this goal, given that all
the caveats will need to be adequately addressed. However, the next step should be to
use nuclear transfer techniques to examine the role of the placenta in the IF phenotype.
Furthermore, the phenotype of IF androgenetic embryos needs to be more closely
examined. For instance, are they same size as androgenotes? How does their expression
profile compare with that of androgenotes and biparental IF-embryos? Can the IF
androgenetic phenotype be rescued by passaging through the germ line?
Does the definition of imprinting need to be revised? Would it be more accurate
to define an imprint-free state based solely on expression level and not on the
mechanism? For instance, should imprint-free mean biallellic expression at all imprinted
loci? With regard to the Igf2 and Igf2r genes, one could easily envisage that biallelic
expression from both these loci would have little effect on development, as the increase
in Igf2 levels would be balanced by increased clearance by Igf2r. Orthologues of genes
imprinted in mammals are found in other non-eutherian vertebrates, including birds, fish,
reptiles and amphibians, where they are biallelically expressed. Thus, it appears likely
that the ancestor of mammals displayed biallelic expression of the genes that would later
become imprinted. How imprinting evolved is not known, but it is probable that it was
co-opted from a more ancient mechanism of DNA methylation (Jaenisch 1997). Indeed,
even the most primitive vertebrates, the Hagfish and lamprey, have methylated genomes
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but do not employ imprinting (Tweedie, Charlton et al. 1997). Given these observations,
perhaps an imprint-free state should be defined as a return to a more 'ancestral state' in
which the orthologues of all imprinted genes are expressed biallelically.
4.7 General Conclusions
In summary, it is clear that the regulation of imprinting in mammals is a complex
process that is still not fully understood. This study has attempted to address the role that
imprinting plays in development and cancer formation by specifically removing the
methylation marks that maintain imprinted gene expression in ES cells. The analysis of
embryos and adult chimeras derived from these cells demonstrated that loss of
imprinting, as defined by a loss of the methyl marks that regulate imprinted gene
expression, results in altered cell growth characteristics and a predisposition to develop
cancer. A number of imprinted genes may be responsible for this phenotype, including
p57K ip2, Grbl O, Igf2 and Igf2r. However, the most significant proteins affected by LOI
were p53 and pl9A f, two critical mediators of cell cycle arrest, senescence, and of tumor
prevention. Interestingly, neither protein is encoded by an imprinted gene. This raises
the exciting possibility that an unknown imprinted gene acts as a critical regulator of the
p53- p19 Arf pathway. Elucidating the identity of this putative gene will be the challenge
for future studies and will undoubtedly provide further insights into the regulation of cell
growth and tumorigenesis.
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5.0 Appendix I:
Imprinted genes in the mammalian genome.
Table 5.1
Imprinted Loci Chromosome Expressed parental Name
allele; Maternal/Paternal
Gatm 2 M L-arginine: Glucine amidino-
.______ _ transferase
Nnat 2 P Neuronatin
Gnas 2 M Guanine nucleotide binding
protein, alpha stimulating
Gnasxl 2 P Guanine nucleotide binding
protein, alpha stimulating, extra
large
Nesp 2 M Neuroendocrine secretory
protein
Nespas 2 P Neuroendocrine secretory
protein antisense
D1x5 6 M Distal-less homeobox 5
Calcr 6 M Calcitorin receptor
Sgce 6 P Sarcoglycan, epsilon
Peg 10 6 P Paternally expressed gene 10
Neurabin 6 M Neurabin
Pon 3 6 M Paroxonase 3
Pon 2 6 M Paroxonase 2
Asb4 6 M Ankyrin repeat and suppressor
of cytokine signaling
Pegl/Mest 6 P Mesoderm specific transcript
Copg2 6 M Coatomer protein complex
subunit gamma 2
Copg2as 6 P Antisense to Copg2
Mitl/b9 6 P Mest linked imprinted transcript
1I
Napl5 6 P Nucleosome assemble protein 1,
like 5.
Zim2 7 M Imprinted zinc-finger gene 2
Ziml 7 M Imprinted zinc-finger gene 1
Peg3/Pwl 7 P Paternally expressed gene 3
Usp29 7 P Ubiquitin specific processing
protease 29
Zim3 7 M Zinc Finger Gene 3 from
Imprinted domain
Zfp264 7 P Zinc Finger ene 264
Snrpn 7 P Small nuclear ribonucleoprotein
polypeptide N
Snurf 7 P Snrpn upstream reading frame
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Pwcrl 7 P Prader-Willi chromosome region
1
Magel2 7 P Magel2
Ndn 7 P Necdin
Zfpl27/Mkrn3 7 P Ring zinc-finger encoding gene
Zfpl27as/Mkrn3as 7 P Ring zinc-finger encoding gene
antisense
Frat3 7 P Frequently rearranged in
advanced T-cell lymphomas.
Ipw 7 P Imprinted in Prader-Willi
Syndrome
Atpl OcAtplOa 7 M Aminophospholipid translocasi
Ube3a 7 M E6-AP ubiquitin protein ligase
.__ _ __ 3A
Ube3aas 7 P Ube3a antisense
InppSf v2 7 P Inositol polyphosphate-5-
phosphatase, varient 2
NaplJ4/Nap2 7 M Nucleosome assembly protein 1 -
like 4
H19 7 M A cDNA clone isolated from a
fetal hepatic library
1gf2 7 P Insulin-like growth factor type 2
Igf2as 7 P Insulin-like growth factor type 2,
antisense
Ins2 7 P Insulin 2
Mash2 7 M Mus musculus achaete-scute
homologue 2
Kvlqtl 7 M Potassium voltage - gated
channel subfamily KQT member
1
Kvlqtlas/Litl/Kcnglotl 7 P Kvlqtl antisense
Tapal/Cd81 7 M Cd 81 anti en
pS7KIP2/Cdknlc 7 M Cyclin-dependent kinase
inhibitor 1C
Msuit 7 M Mouse specific ubiquitously
expressed imprinted transcript 1
Slc2211 7 M Solute carrier family 22 (organic
cation transporter memter-1
like).
Ipl/Tssc3/Phlda2 7 M Pleckstrin homology-like
domain, Family A, member 2
Tssc4 7 M Tumour suppressing
subchromosomal transferable
fragment 4
Obphl 7 M Oxysterol-binding protein 1
A19 9 P
Rasgrfl 9 P Ras protein specific guanine
nucleotide-releasing factor 1
Zacl 10 P Zinc finger DNA binding protein
Dcn 10 M Decorin
Megl/GrblO 11 M Growth factor receptor bound
protein 10
U2afl- rsl 11 P U2 small nuclear
ribonucleoprotein auxiliary
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Murrl
Dlk/Prefl
Meg3/Gtl2
Dio3
Rian
Rtll/Pegll
Rtllas/antiPegll
Mirg
Htr2a
Slc38a4/Ata3
Peg13
Slc22a2
Slc22a3
Igf2r
Igf2ras/Air
Impact
11
12
12
12
12
12
12
12
14
15
15
17
17
17
17
18
M
P
M
P
M
P
M
M
M
P
P
M
M
M
P
P
factor (U2AF), 35kDa, related
sequence 1
U2afl-rsl region 1
Delta like 1
Gene trap locus 2
Deiodinase Iodothyronine Type 3
RNA imprinted and
accumulated in the nucleus.
Retrotransposone-like gene 1
Antisense to Rtll/Peg11
MicroRNA containing gene
5-hydroxytryptamine (serotonin)
receptor 2 A
Solute carrier family 38, member
4/Amino acid transport system
A3
Paternally expressed gene 13
Membrane spanning transporter
protein
Membrane spanning transporter
protein
Insulin-like growth factor type 2
receptor
Insulin-like growth factor type 2
receptor antisense RNA
Homology with yeast & bacterial
protein family YCR59c/yigZ
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